PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Claims

1. A peptide consisting of the amino acid sequence TYETVMTFF (SEQ ID NO: 298) in the form of a pharmaceutically acceptable salt.

2. The peptide of claim 1, wherein said peptide has the ability to bind to an MHC class-I molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD8 T cells.

3. The peptide of claim 1, wherein the pharmaceutically acceptable salt is chloride salt.

4. The peptide of claim 1, wherein the pharmaceutically acceptable salt is acetate salt.

5. A composition comprising the peptide of claim 1, wherein the composition comprises an adjuvant and a pharmaceutically acceptable carrier.

6. The composition of claim 5, wherein the peptide is in the form of a chloride salt.

7. The composition of claim 5, wherein the peptide is in the form of an acetate salt.

8. The composition of claim 5 wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

9. The composition of claim 8, wherein the adjuvant is IL-2.

10. The composition of claim 8, wherein the adjuvant is IL-7.

11. The composition of claim 8, wherein the adjuvant is IL-12.

12. The composition of claim 8, wherein the adjuvant is IL-15.

13. The composition of claim 8, wherein the adjuvant is IL-21.

14. A pegylated peptide consisting of the amino acid sequence of TYETVMTFF (SEQ ID NO: 298) or a pharmaceutically acceptable salt thereof.

15. The peptide of claim 14, wherein the pharmaceutically acceptable salt is chloride salt.

16. The peptide of claim 14, wherein the pharmaceutically acceptable salt is acetate salt.

17. A composition comprising the pegylated peptide of claim 14 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. The composition of claim 5, wherein the pharmaceutically acceptable carrier is selected from the group consisting of saline, Ringer's solution, dextrose solution, and sustained release preparation.

19. The peptide in the form of a pharmaceutically acceptable salt of claim 1, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.

20. A composition comprising the peptide of claim 1, wherein the composition is a pharmaceutical composition and comprises water and a buffer.

Description

FIGURES

[0320] FIGS. 1A through 1J show the over-presentation of various peptides in different cancer tissues (black dots). Upper part: Median MS signal intensities from technical replicate measurements are plotted as dots for single HLA-A*24 positive normal (grey dots, left part of figure) and tumor samples (black dots, right part of figure) on which the peptide was detected. Boxes display median, 25th and 75th percentile of normalized signal intensities, while whiskers extend to the lowest data point still within 1.5 interquartile range (IQR) of the lower quartile, and the highest data point still within 1.5 IQR of the upper quartile. Normal organs are ordered according to risk categories (blood cells, blood vessels, brain, liver, lung: high risk, grey dots; reproductive organs, breast, prostate: low risk, grey dots; all other organs: medium risk; grey dots). Lower part: The relative peptide detection frequency in every organ is shown as spine plot. Numbers below the panel indicate number of samples on which the peptide was detected out of the total number of samples analyzed for each organ (N=75 for normal samples, N=263 for tumor samples). If the peptide has been detected on a sample but could not be quantified for technical reasons, the sample is included in this representation of detection frequency, but no dot is shown in the upper part of the figure. Tissues (from left to right): Normal samples: blood cells; bloodvess (blood vessels); brain; heart; liver; lung; adrenal gl (adrenal gland); bile duct; gall bl (gallbladder); intest. Ia (large intestine); intest. sm (small intestine); kidney; nerve perith (peripheral nerve); pancreas; pituit (pituitary); skin; spinal cord; spleen; stomach; thyroid. Tumor samples: AML (acute myeloid leukemia); BRCA (breast cancer); CCC (cholangiocellular carcinoma); CLL (chronic lymphocytic leukemia); CRC (colorectal cancer); GBC (gallbladder cancer); GBM (glioblastoma); GC (gastric cancer); HCC (hepatocellular carcinoma); HNSCC (head and neck squamous cell carcinoma); MEL (melanoma); NHL (non-Hodgkin lymphoma); NSCLCadeno (non-small cell lung cancer adenocarcinoma); NSCLCother (NSCLC samples that could not unambiguously be assigned to NSCLCadeno or NSCLCsquam); NSCLCsquam (squamous cell non-small cell lung cancer); OC (ovarian cancer); OSCAR (esophageal cancer); PACA (pancreatic cancer); PRCA (prostate cancer); RCC (renal cell carcinoma); SCLC (small cell lung cancer); UBC (urinary bladder carcinoma); UEC (uterine and endometrial cancer). FIG. 1A) Gene symbol: SLC6A3, Peptide: FMVIAGMPLF (SEQ ID NO.: 15), FIG. 1B) Gene symbol: KLHDC7B, Peptide: RYSPVKDAW (SEQ ID NO.: 60), FIG. 1C) Gene symbol: CAPN6, Peptide: NYVLVPTMF (SEQ ID NO.: 74), FIG. 1D) Gene symbol: SYT12, Peptide: SYLPTAERL (SEQ ID NO.: 86), FIG. 1E) Gene symbol: PTPRZ1, Peptide: VYDTMIEKFA (SEQ ID NO.: 202), FIG. 1F) Gene symbol: PTPRZ1, Peptide: EYSLPVLTF (SEQ ID NO.: 274), FIG. 1G) Gene symbol: LOC100124692, Peptide: NYMDTDNLMF (SEQ ID NO.: 362), FIG. 1H) Gene symbol: AR, Peptide: YQSRDYYNF (SEQ ID NO.: 386), FIG. 1I) Gene symbol: CT45A4, CT45A5, Peptide: VGGNVTSNF (SEQ ID NO.: 463), and FIG. 1J) Gene symbol: CT45A1, CT45A2, CT45A3, CT45A4, CT45A6, LOC101060208, LOC101060210, LOC101060211, Peptide: VGGNVTSSF (SEQ ID NO.: 464).

[0321] FIGS. 2A through 2Q show exemplary expression profile of source genes of the present invention that are over-expressed in different cancer samples. Tumor (black dots) and normal (grey dots) samples are grouped according to organ of origin. Box-and-whisker plots represent median FPKM value, 25th and 75th percentile (box) plus whiskers that extend to the lowest data point still within 1.5 interquartile range (IQR) of the lower quartile and the highest data point still within 1.5 IQR of the upper quartile. Normal organs are ordered according to risk categories. FPKM: fragments per kilobase per million mapped reads. Tissues (from left to right): Normal samples: blood cells; bloodvess (blood vessels); brain; heart; liver; lung; adipose (adipose tissue); adrenal gl (adrenal gland); bile duct; bladder; bone marrow; esoph (esophagus); eye; gall bl (gallbladder); head&neck; intest. Ia (large intestine); intest. sm (small intestine); kidney; lymph node; nerve perith (peripheral nerve); pancreas; parathyr (parathyroid gland); perit (peritoneum); pituit (pituitary); pleura; skel. mus (skeletal muscle); skin; spleen; stomach; thyroid; trachea; ureter; breast; ovary; placenta; prostate; testis; thymus; uterus. Tumor samples: AML (acute myeloid leukemia); BRCA (breast cancer); CCC (cholangiocellular carcinoma); CLL (chronic lymphocytic leukemia); CRC (colorectal cancer); GBC (gallbladder cancer); GBM (glioblastoma); GC (gastric cancer); HCC (hepatocellular carcinoma); HNSCC (head and neck squamous cell carcinoma); MEL (melanoma); NHL (non-Hodgkin lymphoma); NSCLCadeno (non-small cell lung cancer adenocarcinoma); NSCLCother (NSCLC samples that could not unambiguously be assigned to NSCLCadeno or NSCLCsquam); NSCLCsquam (squamous cell non-small cell lung cancer); OC (ovarian cancer); OSCAR (esophageal cancer); PACA (pancreatic cancer); PRCA (prostate cancer); RCC (renal cell carcinoma); SCLC (small cell lung cancer); UBC (urinary bladder carcinoma); UEC (uterine and endometrial cancer). FIG. 2A) Gene symbol: MAGEA4, Peptide: IFPKTGLLII (SEQ ID No.: 1), FIG. 2B) Gene symbol: TRPM8, Peptide: KFLTHDVLTELF (SEQ ID No.: 3), FIG. 2C) Gene symbol: CHRNA9, Peptide: KYYIATMAL (SEQ ID No.: 13), FIG. 2D) Gene symbol: MMP12, Peptide: KYVDINTFRL (SEQ ID No.: 18), FIG. 2E) Gene symbol: SPINK2, Peptide: LYMRFVNTHF (SEQ ID No.: 21), FIG. 2F) Gene symbol: OR51E2, Peptide: FWFDSREISF (SEQ ID No.: 28), FIG. 2G) Gene symbol: MMP1, Peptide: KQMQEFFGL (SEQ ID No.: 31), FIG. 2H) Gene symbol: MAGEC1, Peptide: FSSTLVSLF (SEQ ID No.: 35), FIG. 2I) Gene symbol: ENPP3, Peptide: KTYLPTFETTI (SEQ ID No.: 39), FIG. 2J) Gene symbol: POTEG, POTEH, Peptide: MVLQPQPQLF (SEQ ID No.: 4), FIG. 2K) Gene symbol: OR51E2, Peptide: TQMFFIHAL (SEQ ID No.: 97), FIG. 2L) Gene symbol: MMP11, Peptide: FFFKAGFVWR (SEQ ID No.: 107), FIG. 2M) Gene symbol: MMP11, Peptide: YFLRGRLYW (SEQ ID No.: 122), FIG. 2N) Gene symbol: SLC24A5, Peptide: EYFLPSLEII (SEQ ID No.: 194), FIG. 2O) Gene symbol: SLC24A5, Peptide: MSAIWISAF (SEQ ID No.: 277), FIG. 2P) Gene symbol: ELP4, EXOSC7, KCNG2, TM4SF19, TOP2A, Peptide: HHTQLIFVF (SEQ ID No.: 286), FIG. 2Q) Gene symbol: LAMA3, Peptide: YFGNPQKF (SEQ ID No.: 304).

[0322] FIGS. 3A through 3G show exemplary results of peptide-specific in vitro CD8+ T cell responses of a healthy HLA-A*24+ donor. CD8+ T cells were primed using artificial APCs coated with anti-CD28 mAb and HLA-A*24 in complex with SEQ ID NO: 420 peptide (VYEKNGYIYF, Seq ID NO: 420) (A, left panel), SEQ ID NO: 411 peptide (VYPPYLNYL, Seq ID NO: 411) (B, left panel), SEQ ID NO: 5 peptide (LQPQPQLFFSF, Seq ID NO: 5) (C, left panel), SEQ ID NO: 77 peptide (LYGFFFKI, Seq ID NO: 77) (D, left panel), SEQ ID NO: 76 peptide (IYIYPFAHW, Seq ID NO: 76) (E, left panel), SEQ ID NO: 32 peptide (FYPEVELNF, Seq ID NO: 32) (F, left panel), SEQ ID NO: 23 peptide (VYSSFVFNLF, Seq ID NO: 23) (G, left panel), respectively. After three cycles of stimulation, the detection of peptide-reactive cells was performed by 2D multimer staining with A*24/SEQ ID NO: 420 (A), A*24/SEQ ID NO: 411 (B), A*24/SEQ ID NO: 5 (C), A*24/SEQ ID NO: 77 (D), A*24/SEQ ID NO: 76 (E), A*24/SEQ ID NO: 32 (F), A*24/SEQ ID NO: 23 (G), respectively. Right panels (A) show control staining of cells stimulated with irrelevant A*24/peptide complexes. Viable singlet cells were gated for CD8+ lymphocytes. Boolean gates helped excluding false-positive events detected with multimers specific for different peptides. Frequencies of specific multimer+ cells among CD8+ lymphocytes are indicated.

EXAMPLES

Example 1

[0323] Identification and Quantitation of Tumor Associated Peptides Presented on the Cell Surface

[0324] Tissue Samples

[0325] Patients' tumor tissues were obtained from: Asterand Bioscience (Detroit USA & Royston, Herts, UK), BioServe (Beltsville, Md., USA), Conversant Bio (Huntsville, Ala., USA), Geneticist Inc. (Glendale, Calif., USA), Heidelberg University Hospital (dept. of Neurosurgery, Heidelberg, Germany), Heidelberg University Hospital (General, Visceral and Transplantation Surgery, Heidelberg, Germany), Heidelberg University Hospital (Thoraxklinik, Heidelberg, Germany), Istituto Nazionale Tumori “Pascale” (Molecular Biology and Viral Oncology Unit, Naples, Italy), Kyoto Prefectural University of Medicine (Kyoto, Japan), Leiden University Medical Center (LUMC) (Leiden, Netherlands), Osaka City University (Osaka, Japan), ProteoGenex Inc. (Culver City, Calif., USA), Saint Savvas Hospital (Athens, Greece), Tissue Solutions (Glasgow, UK), University Hospital Bonn (dept. of Internal Medicine III, Hematology and Oncology, Bonn, Germany), University Hospital Tübingen (Dept. of General, Visceral and Transplant Surgery, Tübingen, Germany), University Hospital Tübingen (Dept. of Immunology, Tübingen, Germany), University Hospital Tübingen (Dept. of Urology, Tübingen, Germany), University of Geneva (Division of Oncology, Geneva, Switzerland)

[0326] Normal tissues were obtained from: Asterand Bioscience (Detroit USA & Royston, Herts, UK), BioServe (Beltsville, Md., USA), Capital BioScience Inc. (Rockville, Md., USA), Centre for Clinical Transfusion Medicine Tuebingen (Tübingen, Germany), Geneticist Inc. (Glendale, Calif., USA), Heidelberg University Hospital (Thoraxklinik, Heidelberg, Germany), Kyoto Prefectural University of Medicine (Kyoto, Japan), ProteoGenex Inc. (Culver City, Calif., USA), University Hospital Tübingen (Dept. of General, Visceral and Transplant Surgery, Tübingen, Germany), University Hospital Tübingen (Dept. of Urology, Tübingen, Germany)

[0327] Written informed consents of all patients had been given before surgery or autopsy. Tissues were shock-frozen immediately after excision and stored until isolation of TUMAPs at −70° C. or below.

[0328] Isolation of HLA Peptides from Tissue Samples

[0329] HLA peptide pools from shock-frozen tissue samples were obtained by immune precipitation from solid tissues according to a slightly modified protocol (Falk et al., 1991; Seeger et al., 1999) using the HLA-A*02-specific antibody BB7.2, the HLA-A, -B, C-specific antibody W6/32, the HLA-DR specific antibody L243 and the HLA DP specific antibody B7/21, CNBr-activated sepharose, acid treatment, and ultrafiltration.

[0330] Mass Spectrometry Analyses

[0331] The HLA peptide pools as obtained were separated according to their hydrophobicity by reversed-phase chromatography (nanoAcquity UPLC system, Waters) and the eluting peptides were analyzed in LTQ-velos and fusion hybrid mass spectrometers (ThermoElectron) equipped with an ESI source. Peptide pools were loaded directly onto the analytical fused-silica micro-capillary column (75 μm i.d.×250 mm) packed with 1.7 μm C18 reversed-phase material (Waters) applying a flow rate of 400 nL per minute. Subsequently, the peptides were separated using a two-step 180 minute-binary gradient from 10% to 33% B at a flow rate of 300 nL per minute. The gradient was composed of Solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile). A gold coated glass capillary (PicoTip, New Objective) was used for introduction into the nanoESI source. The LTQ-Orbitrap mass spectrometers were operated in the data-dependent mode using a TOP5 strategy. In brief, a scan cycle was initiated with a full scan of high mass accuracy in the orbitrap (R=30 000), which was followed by MS/MS scans also in the orbitrap (R=7500) on the 5 most abundant precursor ions with dynamic exclusion of previously selected ions. Tandem mass spectra were interpreted by SEQUEST at a fixed false discovery rate (q:0.05) and additional manual control. In cases where the identified peptide sequence was uncertain it was additionally validated by comparison of the generated natural peptide fragmentation pattern with the fragmentation pattern of a synthetic sequence-identical reference peptide.

[0332] Label-free relative LC-MS quantitation was performed by ion counting i.e. by extraction and analysis of LC-MS features (Mueller et al., 2007). The method assumes that the peptide's LC-MS signal area correlates with its abundance in the sample. Extracted features were further processed by charge state deconvolution and retention time alignment (Mueller et al., 2008; Sturm et al., 2008). Finally, all LC-MS features were cross-referenced with the sequence identification results to combine quantitative data of different samples and tissues to peptide presentation profiles. The quantitative data were normalized in a two-tier fashion according to central tendency to account for variation within technical and biological replicates. Thus each identified peptide can be associated with quantitative data allowing relative quantification between samples and tissues. In addition, all quantitative data acquired for peptide candidates was inspected manually to assure data consistency and to verify the accuracy of the automated analysis. For each peptide a presentation profile was calculated showing the mean sample presentation as well as replicate variations. The profiles juxtapose acute myeloid leukemia, breast cancer, cholangiocellular carcinoma, chronic lymphocytic leukemia, colorectal cancer, gallbladder cancer, glioblastoma, gastric cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, non-Hodgkin lymphoma, lung cancer (including non-small cell lung cancer adenocarcinoma, squamous cell non-small cell lung cancer, and small cell lung cancer), ovarian cancer, esophageal cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, urinary bladder carcinoma, uterine and endometrial cancer samples to a baseline of normal tissue samples. Presentation profiles of exemplary over-presented peptides are shown in FIGS. 1A-1J.

[0333] Table 8a and Table 8b show the presentation on various cancer entities for selected peptides, and thus the particular relevance of the peptides as mentioned for the diagnosis and/or treatment of the cancers as indicated (e.g. peptide SEQ ID No. 3 for prostate cancer (PRCA), peptide SEQ ID No. 20 for ovarian cancer (OC) and pancreatic cancer (PACA)).

TABLE-US-00009 TABLE 8a Overview of presentation of selected tumor-associated peptides of the present ivention across entities. AML: acute myeloid leukemia; BRCA: breast cancer; CCC: cholangiocellular carcinoma; CLL: chronic lymphocytic leukemia; CRC: colorectal cancer; GBC: gallbladder cancer; GBM: glioblastoma; GC: gastric cancer; HCC: heptaocellular carcinoma; HNSCC: head and neck squamous cell carcinoma; MEL: melanoma; NHL: non-Hodgkin lymphoma; NSCLCadeno: non-small cell lung cancer adenocarcinoma; NSCLCother: NSCLC samples that could not unambiguously be assigned to NSCLCadeno ro NSCLCsquam; NSCLCsquam: squamous cell non-small cell lung cancer; OC: ovarian cancer; OSCAR: esophageal cancer; PACA: pancreatic cancer; PRCA: prostate cancer; RCC: renal cell carcinoma; SCLC: small cell lung cancer; UBC: urinary bladder carcinoma; UEC: uterine and endometrial cancer. SEQ ID No. Sequence Peptide Presentation on cancer entities   1 IFPKTGLLII NSOLCadeno, NSCLCsquam, OSCAR   2 LYAPTILLW CRC, GC, NSCLCadeno, NSCLCsquam, UEC   3 KFLTHDVLTELF PRCA   4 MVLQPQPQLF NSCLCadeno   5 LQPQPQLFFSF PRCA   6 IVTFMNKTLGTF NSCLCadeno   7 GYPLRGSSI GC   9 TYINSLAIL NSCLCadeno, PRCA, RCC, UBC  10 QYPEFSIEL PRCA  11 RAMCAMMSF PACA  12 KYMSRVLFVY CCC  13 KYYIATMAL GC  14 YYIATMALI PRCA  15 FMVIAGMPLF AML, CLL, GC, HCC, NHL, NSCLCother  16 GYFLAQYLM RCC  17 IYPEAIATL BRCA, NSCLCadeno, NSCLCother, RCC  18 KYVDINTFRL NSCLCsquam  19 ILLCMSLLLF NSCLCadeno, NSCLCsquam, PRCA  20 ELMAHPFLL OC, PACA  21 LYMRFVNTHF AML  22 VYSSFVFNL NHL  23 VYSSFVFNLF NHL  24 KMLPEASLLI NHL  25 MLPEASLLI NHL  26 TYFFVDNQYW NSCLCsquam, OSCAR  27 LSCTATPLF NSCLCadeno  28 FWFDSREISF PRCA  29 IYLLLPPVI NSCLCadeno, PRCA  30 RQAYSVYAF PRCA  31 KQMQEFFGL GC, NSCLCsquam  32 FYPEVELNF CCC, UBC  33 FYQPDLKYLSF NHL  34 LIFALALAAF UEC  35 FSSTLVSLF OC  36 VYLASVAAF PRCA  37 ISFSDTVNVW RCC  38 RYAHTLVTSVLF BRCA, MEL  39 KTYLPTFETTI UEC  40 NYPEGAAYEF NSCLCadeno, OC  41 IYFATQVVF PRCA  42 VYDSIWCNM UEC  43 KYKDHFTEI BRCA, GBC, NHL, NSCLCadeno, NSCLCsquam  44 FYHEDMPLW NHL  45 YGQSKPWTF HCC, HNSCC, NSCLCadeno, NSCLCsquam, OSCAR, RCC   46 IYPDSIQEL HCC  47 SYLWTDNLQEF OSCAR  48 AWSPPATLFLF GC, MEL, NSCLCsquam, OC, RCC  49 QYLSIAERAEF GC, UBC  50 RYFDENIQKF OSCAR  51 YFDENIQKF NSCLCsquam, OSCAR  52 SWHKATFLF AML  53 LFQRVSSVSF HCC  54 SYQEAIQQL PRCA  55 AVLRHLETF CCC  56 FYKLIQNGF AML  57 RYLQVVLLY GC  58 IYYSHENLI CCC, CRC, GC, HCC, NSCLCadeno, NSCLCsquam, OC, PRCA  59 VFPLVTPLL GBM  60 RYSPVKDAW CCC, GBC, NHL, NSCLCadeno, NSCLCother, NSCLCsquam, OC, OSCAR  61 RIFTARLYF NHL  62 VYIVPVIVL GBM, NSCLCsquam  63 LYIDKGQYL GBM, HNSCC, MEL, NSCLCadeno, NSCLCsquam  64 QFSHVPLNNF NSCLCsquam  65 EYLLMIFKLV NSCLCadeno, NSCLCsquam, PRCA  66 IYKDYYRYNF NHL  67 SYVLQIVAI GBM, MEL  68 VYKEDLPQL CLL, NSCLCsquam  69 KWFDSHIPRW GBC  70 RYTGQWSEW UBC  71 RYLPNPSLNAF HCC, NSCLCadeno  72 RWLDGSPVTL NHL  73 YFCSTKGQLF CLL, NHL  74 NYVLVPTMF CCC, CRC, GBC, GC, HCC, NSCLCadeno, NSCLCsquam, OC, UEC  75 VYEHNHVSL UBC  76 IYIYPFAHW HCC, NHL  77 LYGFFFKI GC, HCC, UBC  78 TYSKTIALYGF UBC  79 FYIVTRPLAF NHL, NSCLCadeno  80 SYATPVDLW AML, CCC, MEL, NSCLCsquam  81 AYLKLLPMF BRCA, HNSCC, MEL  82 SYLENSASW BRCA, HNSCC, NSCLCadeno, OSCAR, SCLC, UEC  83 VLQGEFFLF NHL  84 YTIERYFTL GC, NSCLCsquam, UEC  85 KYLSIPTVFF CCC, GBC, GC, HCC, NSCLCadeno, PRCA, RCC, UBC  86 SYLPTAERL GBC, GBM, GC, HCC, NSCLCadeno, NSCLCother, NSCLCsquam, PACA, PRCA, UEC  87 NYTRLVLQF CCC, GBC, GC, NSCLCsquam, OSCAR, UEC  88 TYVPSTFLV CCC, GBM, GC, NSCLCsquam, OSCAR, PACA  89 TYVPSTFLVVL GC  90 TDLVQFLLF RCC  91 KQQVVKFLI PRCA  92 RALTETIMF UEC  93 TDWSPPPVEF NSCLCsquam  94 THSGGTNLF NSCLCadeno  95 IGLSVVHRF PRCA  96 SHIGVVLAF PRCA  97 TQMFFIHAL PRCA  98 LQIPVSPSF MEL  99 ASAALTGFTF OC, PRCA 100 KVWSDVTPLTF CCC, NSCLCsquam, PACA 101 VYAVSSDRF GBM 102 VLASAHILQF NSCLCadeno 103 EMFFSPQVF CRC, HCC, NSCLCadeno 104 GYGLTRVQPF NSCLCadeno 105 ITPATALLL NHL 106 LYAFLGSHF RCC 107 FFFKAGFVWR NSCLCsquam, UEC 108 WFFQGAQYW HCC 109 AQHSLTQLF GBM 110 VYSNPDLFW NSCLCadeno 111 IRPDYSFQF NSCLCadeno 112 LYPDSVFGRLF OC 113 ALMSAFYTF NSCLCsquam 114 KALMSAFYTF CCC 115 IMQGFIRAF NSCLCadeno 116 TYFFVANKY GC 117 RSMEHPGKLLF NSCLCadeno, UEC 118 IFLPFFIVF GC 119 VWSCEGCKAF UBC 120 VYAFMNENF RCC 121 RRYFGEKVAL PRCA 122 YFLRGRLYW NSCLCsquam, OC 123 FFLQESPVF HCC 124 EYNVFPRTL CRC, GC, NSCLCadeno, NSCLCsquam 125 LYYGSILYI MEL 126 YSLLDPAQF CRC, NSCLCadeno, PACA, PRCA, UEC 127 FLPRAYYRW PRCA 128 AFQNVISSF GC 129 IYVSLAHVL GC, NSCLCother, NSCLCsquam, PRCA 130 RPEKVFVF NSCLCadeno 131 MHRTWRETF PRCA 132 TFEGATVTL CRC, MEL, NHL 133 FFYVTETTF NHL 134 IYSSQLPSF CLL 135 KYKQHFPEI HCC 136 YLKSVQLF NSCLCsquam 137 ALFAVOWAPF NSCLCsquam 138 MMVTVVALF NSCLCsquam, RCC 139 AYAPRGSIYKF GBC, NSCLCadeno 140 IFQHFCEEI CLL 141 QYAAAITNGL NSCLCsquam 142 PYWWNANMVF NHL 143 KTKRWLWDF NSCLCadeno, NSCLCsquam 144 LFDHGGTVFF GBM 145 MYTIVTPML GC 146 NYFLDPVTI BRCA, MEL, NSCLCadeno, NSCLCsquam, OC 147 FPYPSSILSV GBM 148 MLPQIPFLLL OC 149 TQFFIPYTI CCC, GC, NSCLCsquam, OC 150 FIPVAWLIF OC 151 RRLWAYVTI MEL 152 MHPGVLAAFLF NSCLCadeno 153 AWSPPATLF MEL 154 DYSKQALSL NSCLCadeno 155 PYSIYPHGVTF HCC 156 IYPHGVTFSP GC 157 SIYPHGVTF PRCA 158 SYLKDPMIV CLL 159 VFQPNPLF UEC 160 YIANLISCF GBC 161 ILQAPLSVF CLL, GC, MEL, NSCLCadeno, NSCLCother, NSCLCsquam, OSCAR, PACA, RCC, SCLC 162 YYIGIVEEY HCC, NSCLCsquam 163 YYIGIVEEYW GC 164 MFQEMLQRL MEL 165 KDQPQVPCVF GC 166 MMALWSLLHL NSCLCsquam 167 LQPPWTTVF GC, MEL, NSCLCadeno, NSCLCsquam 168 LSSPVHLDF CRC, HCC, NHL, NSCLCadeno, OSCAR, RCC, UEC 169 MYDLHHLYL NSCLCsquam 170 IFIPATILL HCC 171 LYTVPFNLI NSCLCsquam 172 RYFIAAEKILW HNSCC 173 RYLSVCERL NSCLCsquam 174 TYGEEMPEEI PRCA 175 SYFEYRRLL NSCLCadeno 176 TQAGEYLLF AML 177 KYLITTFSL NSCLCadeno 178 AYPQIRCTW AML 179 MYNMVPFF NSCLCadeno 180 IYNKTKMAF SCLC 181 IHGIKFHYF GC 182 AQGSGTVTF CLL 183 YQVAKGMEF NSCLCadeno 184 VYVRPRVF NSCLCadeno 185 LYICKVELM GC 186 RRVTWNVLF NSCLCsquam 187 KWFNVRMGFGF NHL 188 SLPGSFIYVF NSCLCadeno, RCC 189 FYPDEDDFYF NSCLCother 190 IYIIMQSCW AML 191 MSYSCGLPSL GC, HCC 192 CYSFIHLSF HCC, NHL 193 KYKPVALQCIA NSCLCadeno 194 EYFLPSLEII CLL 195 IYNEHGIQQI GBM, NSCLCadeno, NSCLCsquam 196 VGRSPVFLF GC 197 YYHSGENLY GC, NSCLCadeno 198 VLAPVSGQF CLL, GBC, GC, MEL, NHL, NSOLCadeno, NSCLCsquam, SCLC 199 MFQFEHIKW NSCLCadeno 200 LYMSVEDFI NSCLCother 201 VFPSVDVSF CRC, GBM 202 VYDTMIEKFA GBM, NSCLCadeno, NSCLCother, NSCLCsquam 203 VYPSESTVM GBM 204 WQNVTPLTF NSCLCsquam 205 ISWEVVHTVF PACA 206 EVVHTVFLF GBC, MEL, NSCLCadeno, NSCLCsquam, PRCA, SCLC 207 IYKFIMDRF AML, GBC, GC, HCC, NSCLCadeno, NSCLCother, NSCLCsquam, OSCAR, PRCA, UBC 208 QYLQQQAKL NSCLCadeno 209 DIYVTGGHLF PRCA 210 EAYSYPPATI NSCLCadeno, NSCLCsquam 211 MLYFAPDLIL GC 212 VYFVQYKIM UBC 213 FYNRLTKLF NSCLCadeno 214 YIPMSVMLF NSCLCadeno 215 KASKITFHW GBM 216 RHYHSIEVF HCC 217 QRYGFSSVGF HCC 218 FYFYNCSSL UEC 219 KVVSGFYYI GC 220 TYATHVTEI GC 221 VFYCLLFVF CCC, NSCLCsquam 222 HYHAESFLF OSCAR 223 KLRALSILF PRCA 224 AYLQFLSVL NSCLCother 225 ISMSATEFLL OSCAR 226 TYSTNRTMI CCC 227 YLPNPSLNAF CLL, GC, NSCLCadeno, NSCLCsquam 228 VYLRIGGF MEL, NSCLCadeno, NSCLCsquam, OSCAR, PRCA, RCC, SCLC, UBC 229 CAMPVAMEF NHL 230 RWLSKPSLL NHL 231 KYSVAFYSLD GC 232 IWPGFTTSI GC 233 LYSRRGVRTL OC 234 RYKMLIPF PRCA 235 VYISDVSVY NSCLCadeno 236 LHLYCLNTF CCC 237 RQGLTVLTW NSCLCadeno 238 YTCSRAVSLF NSCLCadeno 239 IYTFSNVTF GC 240 RVHANPLLI HCC 241 QKYYITGEAEGF OSCAR 242 SYTPLLSYI MEL 243 ALFPMGPLTF CLL 244 TYIDTRTVFL HCC 245 VLPLHFLPF RCC 246 KIYTTVLFANI HCC 247 VHSYLGSPF RCC 248 CWGPHCFEM NSCLCsquam 249 HQYGGAYNRV OC 250 VYSDRQIYLL HCC 251 DYLLSWLLF GC 252 RYLIIKYPF GBC 253 QYYCLLLIF NSCLCadeno, NSCLCsquam 254 KQHAWLPLTI NHL 255 VYLDEKQHAW CLL, NHL 256 QHAWLPLTI NHL 257 MLILFFSTI MEL 258 VCWNPFNNTF CRC 259 FFLFIPFF NSCLCadeno 260 FLFIPFFIIF GC 261 IMFCLKNFWW NSCLCadeno, OC 263 AYVTEFVSL BRCA, GBC 264 AYAIPSASLSW HCC 265 LYQQSDTWSL HCC, NSCLCadeno 266 TQIITFESF MEL 267 QHMLPFWTDL OSCAR 268 YQFGWSPNF GC 269 FSFSTSMNEF PRCA 270 GTGKLFWVF PACA 271 INGDLVFSF CLL 272 IYFNHRCF NSCLCadeno 273 VTMYLPLLL GC, NSCLCadeno, NSCLCsquam, OC, RCC 274 EYSLPVLTF AML, CCC, CLL, CRC, GBC, GBM, GC, HCC, HNSCC, MEL, NSCLCadeno, NSCLCother, NSCLCsquam, OC, OSCAR, RCC, SCLC, UBC, UEC 275 PEYSLPVLTF NHL 277 MSAIWISAF OSCAR 278 TYESVVTGFF SCLC 279 KYKNPYGF HCC 280 TIYSLEMKMSF NSCLCother, NSCLCsquam 281 MDQNQVVWTF NSCLCadeno 282 ASYQQSTSSFF NSCLCadeno 283 SYIVDGKII PRCA 284 QFYSTLPNTI HCC 285 YFLPGPHYF RCC 286 HHTQLIFVF GBC, PRCA 287 LVQPQAVLF GBM, GC, NSCLCadeno, SCLC, UEC 288 MGKGSISFLF NSCLCadeno 289 RTLNEIYHW NSCLCadeno, NSCLCsquam 290 VTPKMLISF CCC, NSCLCother 291 YTRLVLQF AML, BRCA, CCC, CLL, CRC, GBC, GBM, GC, HCC, HNSCC, MEL, NHL, NSCLCadeno, NSCLCother, NSCLCsquam, OC, OSCAR, PACA, PRCA, RCC, SCLC, UBC, UEC 292 KMFPKDFRF CRC 293 MYAYAGWFY CRC 294 KMGRIVDYF CCC, GBC, GC 295 KYNRQSMTL HCC 296 YQRPDLLLF CLL, MEL 297 LKSPRLFTF GBC 298 TYETVMTFF GBC, GC, HCC, NHL, UBC 299 FLPALYSLL NSCLCadeno 300 LFALPDFIF NSCLCadeno 301 RTALSSTDTF NHL 302 YQGSLEVLF NSCLCadeno 303 RFLDRGWGF CRC 304 YFGNPQKF GC, PACA 305 RNAFSIYIL CRC, NSCLCadeno 306 RYILEPFFI BRCA, CCC, CRC, GBC, GBM, GC, HCC, HNSCC, MEL, NHL, NSCLCadeno, NSCLCother, NSCLCsquam, OC, OSCAR, PACA, PRCA, RCC, SCLC, UBC, UEC 307 RILTEFELL GC 308 AAFISVPLLI HCC 309 AFISVPLLI NSCLCadeno, NSCLCother 310 EFINGWYVL HCC 311 IQNAILHLF SCLC 312 YLCMLYALF CCC, GBC, GC, NHL 313 IFMENAFEL HCC 315 VYDYIPLLL OC 316 IWAERIMF NSCLCsquam 317 DWIWRILFLV GBM 318 VQADAKLLF GC, NSCLCadeno, UBC 319 ATATLHLIF UEC 320 EVYQKIILKF GBC 321 VYTVGHNLI HCC 322 SFISPRYSWLF AML, CRC, NSCLCadeno, NSCLCsquam, UBC 323 NYSPVTGKF OSCAR 324 RYFVSNIYL GC, NSCLCadeno, NSCLCsquam, UEC 325 IFMGAVPTL HNSCC, NSCLCadeno, OC, OSCAR 326 VHMKDFFYF CLL, MEL, NHL, NSCLCadeno, NSCLCsquam, OC, PACA 328 IYLVGGYSW CLL 329 YLGKNWSF AML, CCC 330 DYIQMIPEL BRCA, GBC, GC, SCLC 332 VYCSLDKSQF BRCA, CCC, GBC, GC, MEL 333 RYADLLIYTY UEC 334 KVFGSFLTL UEC 335 RYQSVIYPF UEC 336 VYSDLHAFY CCC, GBC, HCC, NSCLCadeno, PACA 337 SHSDHEFLF UEC 338 VYLTWLPGL CLL, NHL 339 KQVIGIHTF CLL, GBC, GBM, GC, RCC 340 FPPTPPLF AML 341 RYENVSILF GBM, OC 342 MYGIVIRTI GC 343 EYQQYHPSL NHL 344 YAYATVLTF GBC, GC, NHL, NSCLCadeno, UBC 345 RYLEEHTEF GBC, NSCLCadeno, OC, UEC 346 TYIDFVPYI GBC, GC, NSCLCadeno, OC, RCC, UEC 347 AWLIVLLFL NHL, UEC 348 RSWENIPVTF CCC 349 IYMTTGVLL GC, NSCLCadeno 350 VYKWTEEKF BRCA, NSCLCother, OSCAR 351 GYFGTASLF NSCLCadeno, NSCLCother 352 NAFEAPLTF OC 353 AAFPGAFSF OC 354 QYIPTFHVY BRCA, GBM, HCC, HNSCC, NSCLCsquam, OSCAR 355 VYNNNSSRF CCC, CRC, GBC, GC, HCC, HNSCC, MEL, NHL, NSCLCadeno, NSCLCother, NSCLCsquam, OC, OSCAR, PACA, PRCA, RCC, SCLC, UEC 356 YSLEHLTQF OC, UEC 357 RALLPSPLF MEL, NHL 358 IYANVTEMLL OSCAR 359 TQLPAPLRI UEC 360 LYITKVTTI NSCLCadeno 361 KQPANFIVL GBC 362 NYMDTDNLMF CCC, GBC, GC, HCC, OC, OSCAR, SCLC 363 QYGFNYNKF GC, NSCLCsquam 364 KQSQVVFVL NSCLCsquam, OC, PRCA 365 KDLMKAYLF GC, SCLC 366 RLGEFVLLF GC 367 HWSHITHLF CCC, CRC, GBM, GC, MEL 368 AYFVAMHLF GBC, GBM, HNSCC, MEL, NHL, NSCLCadeno, NSCLCother, NSCLCsquam, OC, SCLC, UEC 369 NFYLFPTTF GC, NSCLCsquam 370 TQMDVKLVF GBC, GC, HCC, NHL, NSCLCadeno, NSCLCsquam, OSCAR, UBC, UEC 371 FRSWAVQTF AML, CRC, GC 372 LYHNWRHAF BRCA, OC, RCC 373 IWDALERTF CLL, CRC, GBC, GBM, GC, HCC, HNSCC, MEL, NHL, NSCLCadeno, NSCLCsquam, OC, OSCAR, PRCA 374 MIFAVVVLF GBC, GBM, GC, MEL, NHL, NSCLCadeno, OC, OSCAR, PRCA 375 YYAADQWVF AML, GBC, GC, HCC, NHL, NSCLCadeno, NSCLCother,  NSCLCsquam, OSCAR, PACA 376 KYVGEVFNI AML, CLL, HCC, NHL, NSCLCadeno, NSCLCsquam, RCC 377 SLWREVVTF OC, RCC 378 VYAVISNIL GBM, NHL, NSCLCadeno, SCLC 379 KLPTEWNVL CCC, CLL, CRC, GC, HCC, NHL, NSCLCadeno, NSCLCother, OSCAR, RCC, UEC 380 FYIRRLPMF NHL, NSCLCadeno, NSCLCsquam, OC, OSCAR, RCC 381 IYTDITYSF AML, CCC, GBC, HCC, NHL, NSCLCadeno, NSCLCsquam, OC, OSCAR, RCC 382 SYPKELMKF GBC, GC, HNSCC, NSCLCadeno, OC, UEC 383 PYFSPSASF NSCLCadeno, NSCLCother, UBC 385 GYFGNPQKF BRCA, CCC, CRC, GBC, GC, HCC, HNSCC, MEL, NSCLCadeno, NSCLCother, NSCLCsquam, OC, OSCAR, PACA, PRCA, RCC, SCLC, UBC, UEC 386 YQSRDYYNF CRC, GBC, GBM, GC, HCC, HNSCC, NSCLCadeno, NSCLCsquam, OC, PRCA, UBC, UEC 387 THAGVRLYF CRC, GBC, GC, HCC, NHL, NSCLCadeno, NSCLCsquam, OC, OSCAR, PRCA, UEC

TABLE-US-00010 TABLE 8b Overvies of presentation of selected tumor- associated peptides of the present invention across entities. AML: acute myeloid leukemia; BRCA: breast cancer; GBC: gallbladder cancer; GC: gastric cancer; HCC: hepatocellular carcinoma; HNSCC: head and neck squamous cell carcinoma; NSCLCadeno: non-small cell lung canger adenocarconoma; NSCLCsquam: squamous cell non-small cell lung cancer; OC: ovarian cancer;. SEQ Peptide Presentation ID No. Sequence on cancer entities 463 VGGNVTSNF AML, BRCA, GBC, GC, HCC,  HNSCC, NSCLCsquam, OC 464 VGGNVTSSF BRCA, GBC, GC, HNSCC,  NSCLCadeno, NSCLCsquam, OC

Example 2

[0334] Expression Profiling of Genes Encoding the Peptides of the Invention

[0335] Over-presentation or specific presentation of a peptide on tumor cells compared to normal cells is sufficient for its usefulness in immunotherapy, and some peptides are tumor-specific despite their source protein occurring also in normal tissues. Still, mRNA expression profiling adds an additional level of safety in selection of peptide targets for immunotherapies. Especially for therapeutic options with high safety risks, such as affinity-matured TCRs, the ideal target peptide will be derived from a protein that is unique to the tumor and not found on normal tissues.

[0336] RNA Sources and Preparation

[0337] Surgically removed tissue specimens were provided as indicated above (see Example 1) after written informed consent had been obtained from each patient. Tumor tissue specimens were snap-frozen immediately after surgery and later homogenized with mortar and pestle under liquid nitrogen. Total RNA was prepared from these samples using TRI Reagent (Ambion, Darmstadt, Germany) followed by a cleanup with RNeasy (QIAGEN, Hilden, Germany); both methods were performed according to the manufacturer's protocol.

[0338] Total RNA from healthy human tissues for RNASeq experiments was obtained from: Asterand (Detroit, Mich., USA & Royston, Herts, UK); Bio-Options Inc. (Brea, Calif., USA); Geneticist Inc. (Glendale, Calif., USA); ProteoGenex Inc. (Culver City, Calif., USA); Tissue Solutions Ltd (Glasgow, UK). Total RNA from tumor tissues for RNASeq experiments was obtained from: Asterand (Detroit, Mich., USA & Royston, Herts, UK); BioCat GmbH (Heidelberg, Germany); BioServe (Beltsville, Md., USA); Geneticist Inc. (Glendale, Calif., USA); Istituto Nazionale Tumori “Pascale” (Naples, Italy); ProteoGenex Inc. (Culver City, Calif., USA); University Hospital Heidelberg (Heidelberg, Germany).

[0339] Quality and quantity of all RNA samples were assessed on an Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) using the RNA 6000 Pico LabChip Kit (Agilent).

[0340] RNAseq Experiments

[0341] Gene expression analysis of—tumor and normal tissue RNA samples was performed by next generation sequencing (RNAseq) by CeGaT (Tübingen, Germany). Briefly, sequencing libraries are prepared using the Illumina HiSeq v4 reagent kit according to the provider's protocol (Illumina Inc., San Diego, Calif., USA), which includes RNA fragmentation, cDNA conversion and addition of sequencing adaptors. Libraries derived from multiple samples are mixed equimolar and sequenced on the Illumina HiSeq 2500 sequencer according to the manufacturer's instructions, generating 50 bp single end reads. Processed reads are mapped to the human genome (GRCh38) using the STAR software. Expression data are provided on transcript level as RPKM (Reads Per Kilobase per Million mapped reads, generated by the software Cufflinks) and on exon level (total reads, generated by the software Bedtools), based on annotations of the ensembl sequence database (Ensembl77). Exon reads are normalized for exon length and alignment size to obtain RPKM values.

[0342] Exemplary expression profiles of source genes of the present invention that are highly over-expressed or exclusively expressed in acute myeloid leukemia, breast cancer, cholangiocellular carcinoma, chronic lymphocytic leukemia, colorectal cancer, gallbladder cancer, glioblastoma, gastric cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, non-Hodgkin lymphoma, lung cancer (including non-small cell lung cancer adenocarcinoma, squamous cell non-small cell lung cancer, and small cell lung cancer), ovarian cancer, esophageal cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, urinary bladder carcinoma, uterine and endometrial cancer are shown in FIGS. 2A-2Q. Expression scores for further exemplary genes are shown in Table 9a and Table 9b.

TABLE-US-00011 TABLE 9a Expression scores. The table lists for each peptide the tumor types for which the exon is very highly over-expressed in tumors compared to a panel of normal tissues (+++), highly over-expressed in tumors compared to a panel of normal tissues (++) or over-expressed in tumors compared to a panel of normal tissues (+). The baseline for this score was calculated from measurements of the following relevant normal tissues: blood cells, blood vessels, brain, heart, liver, lung, adipose tissue,  adrenal gland, bile duct, bone marrow, esophagus, eye, gallbladder, head-and-neck,  kidney, large intestine, lymph node, pancreas, parathyroid gland, peripheral nerve,  peritoneum, pituitary, pleura, skeletal muscle, skin, small intestine, spleen, stomach,  thyroid gland, trachea, ureter, urinary bladder. In case expression data for several samples of the same tissue type were available, the arithmetic mean of all respective samples was used for the calculation. AML: acute myeloid leukemia; BRCA: breast cancer; CCC: cholangiocellular carcinoma; CLL: chronic lymphocytic leukemia; CRC: colorectal cancer; GBC: gallbladder cancer; GBM: glioblastoma; GO: gastric cancer; HOC: hepatocellular carcinoma; HNSCC: head and neck squamous cell carcinoma; MEL: melanoma; NHL: non-Hodgkin lymphoma; NSCLCadeno: non-small cell lung cancer adenocarcinoma; NSCLCother: NSCLC samples that could not unambiguously be assigned to NSCLCadeno or NSCLCsquam; NSCLCsquam: squamous cell non-small cell lung cancer; OC: ovarian cancer; OSCAR: esophageal cancer; PACA: pancreatic cancer; PRCA: prostate cancer; RCC: renal cell carcinoma; SCLC: small cell lung cancer; UBC: urinary bladder carcinoma; UEC: uterine and endometrial cancer. Exon Expression in tumor types vs normal tissue panel Seq highly over- very highly over- ID No Sequence over-expressed (+) expressed (++) expressed (+++)   1 IFPKTGLLII BRCA, CRC, GC,  HCC, NSCLCadeno,  GBC, HNSCC, MEL,  UEC UBC NSCLCsquam, OC,  OSCAR, SCLC   2 LYAPTILLW GBC CCC, HCC   3 KFLTHDVLTELF MEL GBM, SCLC PRCA   4 MVLQPQPQLF GBC, HCC, NHL,  PRCA OC, UBC   5 LQPQPQLFFSF GBC, HCC, NHL,  PRCA OC, UBC   6 IVTFMNKTLGTF NHL CLL   7 GYPLRGSSI OC UEC   8 IMKPLDQDF BRCA, CRC, GBC,  NSCLCadeno PRCA GC,  NSCLCsquam,  PACA, SCLC,  UBC, UEC   9 TYINSLAIL PRCA  10 QYPEFSIEL PRCA  11 RAMCAMMSF PRCA  12 KYMSRVLFVY MEL,  GBM, HNSCC,  NSCLCother NSCLCadeno,  SCLC NSCLCsquam,  OC, OSCAR,  UBC, UEC  13 KYYIATMAL MEL,  GBM, HNSCC,  NSCLCother NSCLCadeno,  SCLC NSCLCsquam,  OC, OSCAR,  UBC, UEC  14 YYIATMALI MEL,  GBM, HNSCC,  NSCLCother NSCLCadeno,  SCLC NSCLCsquam,  OC, OSCAR,  UBC, UEC  15 FMVIAGMPLF NSCLCadeno,  RCC NSCLCsquam  16 GYFLAQYLM GBM, MEL PRCA  17 IYPEAIATL NSCLCadeno RCC  18 KYVDINTFRL HCC, RCC CCC, GC, MEL,  CRC, GBC, HNSCC,  NHL, NSCLCadeno,  NSCLCother,  OC, PACA, UEC NSCLCsquam,  OSCAR, SCLC,  UBC  19 ILLCMSLLLF OC BRCA  20 ELMAHPFLL OC BRCA  21 LYMRFVNTHF AML  22 VYSSFVFNL GBC, GBM, MEL,  CLL NHL OC, UBC  23 VYSSFVFNLF GBC, GBM, MEL,  CLL NHL OC, UBC  24 KMLPEASLLI GBC, GBM, MEL,  CLL NHL OC, UBC  25 MLPEASLLI GBC, GBM, MEL,  CLL NHL OC, UBC  26 TYFFVDNQYW HCC, NHL, RCC CCC, CRC, GBC,  NSCLCother,  GC, HNSCC, MEL,  NSCLCsquam NSCLCadeno, OC,  OSCAR, PACA,  SCLC, UBC, UEC  27 LSCTATPLF NSCLCother,  OSCAR HNSCC NSCLCsquam,  SCLC  28 FWFDSREISF PRCA  29 IYLLLPPVI PRCA  30 RQAYSVYAF PRCA  31 KQMQEFFGL CRC, MEL, PACA GC, NSCLCadeno,  HNSCC NSCLCsquam,  OSCAR, UBC  32 FYPEVELNF CRC, GC, MEL,  HNSCC,  PACA NSCLCadeno,  NSCLCsquam,  OSCAR, UBC  33 FYQPDLKYLSF CLL, GBC NHL  34 LIFALALAAF GBC GC, HNSCC,  NSCLCsquam,  OSCAR, PACA  35 FSSTLVSLF GBC, SCLC HCC, MEL  36 VYLASVAAF PRCA  37 ISFSDTVNVW BRCA, PRCA MEL  38 RYAHTLVTSVLF MEL  39 KTYLPTFETTI UEC RCC  40 NYPEGAAYEF BRCA, OC, UEC  41 IYFATQVVF PRCA  42 VYDSIWCNM OC, UEC  43 KYKDHFTEI BRCA, MEL,  GBC, HCC, NHL NSCLCadeno,  NSCLCsquam,  SCLC  44 FYHEDMPLW NHL CLL  45 YGQSKPWTF MEL  46 IYPDSIQEL HCC  47 SYLWTDNLQEF GBC, SOLC HNSCC,  NSCLCsquam,  OSCAR  48 AWSPPATLFLF CCC MEL  49 QYLSIAERAEF UEC  50 RYFDENIQKF NSCLCother,  HNSCC OSCAR  51 YFDENIQKF NSCLCother,  HNSCC OSCAR  52 SWHKATFLF AML  53 LFQRVSSVSF MEL  54 SYQEAIQQL PRCA  55 AVLRHLETF GBM, GC, OSCAR AML  56 FYKLIQNGF AML  57 RYLQVVLLY GBM, PACA CRC, GBC, GC  58 IYYSHENLI CCC HCC  59 VFPLVTPLL GBM  60 RYSPVKDAW BRCA,  HNSCC NSCLCsquam,  OSCAR, UBC  61 RIFTARLYF NHL  62 VYIVPVIVL GBM, OC CCC  63 LYIDKGQYL MEL  64 QFSHVPLNNF MEL  65 EYLLMIFKLV NHL HNSCC, MEL  66 IYKDYYRYNF MEL NHL  67 SYVLQIVAI GBM  68 VYKEDLPQL NHL  69 KWFDSHIPRW BRCA, CLL, NHL,  UBC RCC  70 RYTGQWSEW AML UBC  71 RYLPNPSLNAF NSCLCother  72 RWLDGSPVTL CLL, NHL  73 YFCSTKGQLF NHL CLL  74 NYVLVPTMF GC UEC  75 VYEHNHVSL UBC  76 IYIYPFAHW GBC HCC  77 LYGFFFKI UBC  78 TYSKTIALYGF UBC  79 FYIVTRPLAF AML CCC  80 SYATPVDLW GBM, GC AML  81 AYLKLLPMF MEL  82 SYLENSASW UEC  83 VLQGEFFLF NHL CLL  84 YTIERYFTL GBC, GC, UEC PACA  85 KYLSIPTVFF HCC  86 SYLPTAERL CCC  87 NYTRLVLQF GBC, GC, UEC PACA  88 TYVPSTFLV GBC, GC, UEC PACA  89 TYVPSTFLVVL GBC, GC, UEC PACA  90 TDLVQFLLF HCC,  GBC, GC, HNSCC,  MEL NSCLCadeno NSCLCsquam, OC,  OSCAR, SCLC,  UBC  91 KQQVVKFLI GC, HNSCC, NHL,  GBC, OC BRCA, PRCA NSCLCsquam,  OSCAR, PACA,  SCLC, UBC, UEC  92 RALTETIMF OC UEC  93 TDWSPPPVEF GC,  GBC, HCC, HNSCC,  MEL NSCLCsquam,  OSCAR PACA, SCLC,  UEC  94 THSGGTNLF HCC, RCC CCC, CRC, GC,  GBC, HNSCC,  MEL, NHL,  NSCLCother,  NSCLCadeno, OC,  NSCLCsquam OSCAR, PACA,  SCLC, UBC, UEC  95 IGLSVVHRF PRCA  96 SHIGWLAF PRCA  97 TQMFFIHAL PRCA  98 LQIPVSPSF GBC, SCLC HCC, MEL  99 ASAALTGFTF PRCA 100 KVWSDVTPLTF HCC, RCC, SCLC BRCA, CCC, CRC,  GBC, GC, HNSCC,  NSCLCadeno,  NSCLCsquam, OC,  OSCAR, PACA,  UBC, UEC 101 VYAVSSDRF GBM, SCLC 102 VLASAHILQF UBC 103 EMFFSPQVF GC, HNSCC, MEL,  BRCA, CCC, CRC,  NSCLCadeno,  GBC, HCC, OC,  NSCLCsquam,  UBC OSCAR, PACA,  RCC, SCLC 104 GYGLTRVQPF GC, HNSCC, MEL,  BRCA, CCC, CRC,  NSCLCadeno,  GBC, HCC, OC,  NSCLCsquam,  UBC OSCAR, PACA,  RCC, SCLC 105 ITPATALLL NHL CLL 106 LYAFLGSHF BRCA,  RCC NSCLCadeno,  UEC 107 FFFKAGFVWR HCC, OC, SCLC BRCA, CCC, CRC,  GBC, GC, HNSCC,  NSCLCadeno,  NSCLCsquam,  OSCAR, PACA,  UBC, UEC 108 WFFQGAQYW HCC, OC BRCA, CCC, CRC,  GBC, GC, HNSCC,  NSCLCadeno,  NSCLCsquam,  OSCAR, PACA,  UBC, UEC 109 AQHSLTQLF GBM, SCLC 110 VYSNPDLFW CLL 111 IRPDYSFQF CLL 112 LYPDSVFGRLF AML, CCC, GC,  BRCA, GBC, HCC,  HNSCC,  MEL, NSCLCadeno,  NSCLCother,  OC, SCLC, UBC NSCLCsquam,  OSCAR, UEC 113 ALMSAFYTF HCC, OC, RCC,  BRCA, CCC, CRC,  SCLC GBC, GC, HNSCC,  NSCLCadeno,  NSCLCsquam,  OSCAR, PACA,  UBC, UEC 114 KALMSAFYTF HCC, OC, RCC,  BRCA, CCC, CRC,  SCLC GBC, GC, HNSCC,  NSCLCadeno,  NSCLCsquam,  OSCAR, PACA,  UBC, UEC 115 IMQGFIRAF CCC, HCC, OC NSCLCadeno 116 TYFFVANKY CRC, GC,  HNSCC,  NSCLCadeno,  NSCLCsquam,  PACA, UBC OSCAR 117 RSMEHPGKLLF BRCA, OC, UEC 118 IFLPFFIVF BRCA, GBC, HCC,  CCC, RCC OSCAR, PRCA,  UBC, UEC 119 VWSCEGCKAF BRCA, OC, UEC 120 VYAFMNENF NSCLCsquam,  RCC OSCAR 121 RRYFGEKVAL PRCA 122 YFLRGRLYW HCC, OC BRCA, CCC, CRC,  GBC, GC, HNSCC,  NSCLCadeno,  NSCLCsquam,  OSCAR, PACA,  UBC, UEC 123 FFLQESPVF HCC, MEL, PRCA BRCA 124 EYNVFPRTL NSCLCadeno,  HNSCC,  UBC NSCLCsquam,  OSCAR 125 LYYGSILYI MEL 126 YSLLDPAQF GBC, HCC,  CRC, GC, PRCA HNSCC,  NSCLCadeno,  NSCLCother,  OSCAR, SCLC,  UBC, UEC 127 FLPRAYYRW PRCA 128 AFQNVISSF NSCLCsquam,  GC, PACA UEC 129 IYVSLAHVL PRCA 130 RPEKVFVF CCC, CRC, GBM,  BRCA, GBC, GC,  NSCLCother,  HNSCC, MEL,  NSCLCsquam,  NSCLCadeno,  OC, SCLC OSCAR, PACA 131 MHRTWRETF PRCA 132 TFEGATVTL NHL CLL 133 FFYVTETTF AML, GC, OC,  HCC, NHL OSCAR, SCLC,  UEC 134 IYSSQLPSF NHL CLL 135 KYKQHFPEI HCC 136 YLKSVQLF BRCA, MEL AML 137 ALFAVCWAPF NSCLCsquam,  RCC OSCAR 138 MMVTVVALF NSCLCsquam,  RCC OSCAR 139 AYAPRGSIYKF BRCA,  HCC NSCLCadeno, OC 140 IFQHFCEEI AML, BRCA, GBC,  OC, SCLC HCC, MEL,  NSCLCadeno 141 QYAAAITNGL SCLC GBM 142 PYWWNANMVF HCC 143 KTKRWLWDF CCC, CRC, GBM,  BRCA, GBC,  GC, NSCLCother,  HNSCC, MEL,  NSCLCsquam, OC NSCLCadeno,  OSCAR, PACA 144 LFDHGGTVFF PRCA 145 MYTIVTPML GBM OC 146 NYFLDPVTI MEL 147 FPYPSSILSV MEL GBM, SCLC 148 MLPQIPFLLL CRC, HNSCC,  BRCA, CCC, GBC,  NSCLCsquam,  GC, NSCLCadeno,  OC, UBC, UEC OSCAR, PACA 149 TQFFIPYTI CRC, HNSCC,  BRCA, CCC, GBC,  NSCLCsquam,  GC, NSCLCadeno,  OC, UBC, UEC OSCAR, PACA 150 FIPVAWLIF HNSCC, UBC MEL 151 RRLWAYVTI MEL 152 MHPGVLAAFLF NSCLCadeno,  HNSCC,  UBC NSCLCsquam,  OSCAR 153 AWSPPATLF CCC MEL 154 DYSKQALSL CCC, GC,  HNSCC,  NSCLCadeno,  NSCLCsquam,  NSCLCother,  OSCAR PACA, UBC, UEC 155 PYSIYPHGVTF CCC HCC 156 IYPHGVTFSP CCC HCC 157 SIYPHGVTF CCC HCC 158 SYLKDPMIV GBC, HNSCC,  HCC MEL,  NSCLCadeno,  SCLC 159 VFQPNPLF GC,  CRC, HNSCC, MEL,  NSCLCsquam,  OC, OSCAR, UBC PACA 160 YIANLISCF SCLC, UEC 161 ILQAPLSVF NHL CLL 162 YYIGIVEEY NSCLCother,  HNSCC OSCAR 163 YYIGIVEEYW NSCLCother,  HNSCC OSCAR 164 MFQEMLQRL BRCA, GBC,  HNSCC, MEL,  NSCLCsquam,  OSCAR, PACA OC, UBC 165 KDQPQVPCVF BRCA 166 MMALWSLLHL SCLC 167 LQPPWTTVF NHL CLL 168 LSSPVHLDF NHL CLL 169 MYDLHHLYL CRC, GBC,  BRCA, GC, MEL,  HNSCC, NHL,  NSCLCadeno, OC,  NSCLCsquam,  OSCAR, PACA UEC 170 IFIPATILL PROA HCC 171 LYTVPFNLI HCC MEL 172 RYFIAAEKILW OSCAR HNSCC 173 RYLSVCERL HNSCC,  NSCLCother NSCLCadeno,  NSCLCsquam,  OSCAR, SCLC,  UEC 174 TYGEEMPEEI NSCLCother,  HNSCC, OSCAR NSCLCsquam 175 SYFEYRRLL GC, NSCLCadeno,  CCC, HNSCC,  NSCLCother,  NSCLCsquam,  PACA, UBC OSCAR 176 TQAGEYLLF AML 177 KYLITTFSL BRCA, GC,  CCC, GBC,  HNSCC, NHL,  NSCLCsquam, OC,  NSCLCadeno,  UBC, UEC OSCAR, PACA,  PRCA, SCLC 178 AYPQIRCTW AML 179 MYNMVPFF MEL 180 IYNKTKMAF HNSCC, MEL, OC,  HCC, UBC OSCAR, SCLC 181 IHGIKFHYF PACA, UEC GC 182 AQGSGTVTF CLL, NHL 183 YQVAKGMEF AML 184 VYVRPRVF MEL 185 LYICKVELM NHL CLL 186 RRVTWNVLF SCLC GBM 187 KWFNVRMGFGF GBC, MEL, OC,  HCC, SCLC UBC, UEC 188 SLPGSFIYVF MEL 189 FYPDEDDFYF GBM, MEL, OC,  AML, UEC SCLC, UBC 190 IYIIMQSCW AML 191 MSYSCGLPSL HNSCC MEL 192 CYSFIHLSF BRCA, CCC, GC,  GBC,  HNSCC, NHL,  NSCLCsquam, OC,  NSCLCadeno,  UBC, UEC OSCAR, PACA,  PRCA, SCLC 193 KYKPVALQCIA MEL 194 EYFLPSLEII MEL 195 IYNEHGIQQI CCC, CRC, GBC,  BRCA, MEL,  GBM, GC,  NSCLCadeno,  HNSCC,  PACA NSCLCother,  NSCLCsquam,  OC, OSCAR 196 VGRSPVFLF CCC, CRC, GBC,  BRCA, MEL,  GBM, GC,  NSCLCadeno,  HNSCC,  PACA NSCLCother,  NSCLCsquam,  OC, OSCAR 197 YYHSGENLY MEL CCC 198 VLAPVSGQF NHL CLL 199 MFQFEHIKW HCC 200 LYMSVEDFI GC, HNSCC, MEL,  CRC, GBC NSCLCadeno,  NSCLCsquam,  OC, OSCAR,  PACA, UBC 201 VFPSVDVSF GBM 202 VYDTMIEKFA GBM 203 VYPSESTVM GBM 204 WQNVTPLTF BRCA GBM, MEL 205 ISWEVVHTVF MEL 206 EVVHTVFLF MEL 207 IYKFIMDRF NHL,  SCLC, UEC NSCLCadeno,  NSCLCsquam, OC 208 QYLQQQAKL NHL,  SCLC, UEC NSCLCadeno,  NSCLCsquam, OC 209 DIYVTGGHLF BRCA,  HNSCC NSCLCsquam,  OSCAR, UBC 210 EAYSYPPATI MEL 211 MLYFAPDLIL BRCA UEC 212 VYFVQYKIM BRCA, HNSCC,  CCC, NHL,  NSCLCother,  NSCLCadeno NSCLCsquam,  OC, OSCAR,  PACA, UBC, UEC 213 FYNRLTKLF CRC, GBC,  OSCAR, UBC HNSCC, MEL,  NHL,  NSCLCadeno,  NSCLCsquam,  OC, PACA, UEC 214 YIPMSVMLF AML,  HNSCC, UBC NSCLCsquam,  OSCAR 215 KASKITFHW GBM 216 RHYHSIEVF MEL 217 QRYGFSSVGF HCC 218 FYFYNCSSL BRCA, CLL, NHL,  UBC ROC 219 KVVSGFYYI BRCA, CCC,  NHL HNSCC, MEL,  NSCLCadeno,  NSCLCother,  NSCLCsquam,  OSCAR, UBC 220 TYATHVTEI BRCA, CCC,  NHL HNSCC, MEL,  NSCLCadeno,  NSCLCother,  NSCLCsquam,  OSCAR, UBC 221 VFYCLLFVF BRCA, CCC,  NHL HNSCC, MEL,  NSCLCadeno,  NSCLCother,  NSCLCsquam,  OSCAR, UBC 222 HYHAESFLF OSCAR HNSCC 223 KLRALSILF GBM 224 AYLQFLSVL BRCA, HCC, MEL,  PRCA OC, SCLC, UEC 225 ISMSATEFLL NSCLCother 226 TYSTNRTMI AML 227 YLPNPSLNAF NSCLCother 228 VYLRIGGF CCC, HNSCC,  OC PACA, UBC, UEC 229 CAMPVAMEF CLL, NHL 230 RWLSKPSLL CLL, NHL 231 KYSVAFYSLD MEL,  OC, UEC NSCLCsquam,  ROC, SCLC 232 IWPGFTTSI GBC, GC, PACA,  CRC SCLC, UEC 233 LYSRRGVRTL CCC, OC PACA 234 RYKMLIPF BRCA, CCC, GC,  GBC, OC, UBC HNSCC, NHL,  NSCLCadeno,  NSCLCsquam,  OSCAR, PACA,  SCLC, UEC 235 VYISDVSVY AML, NHL CLL 236 LHLYCLNTF BRCA UEC 237 RQGLTVLTW AML, BRCA, CRC,  NHL GC, MEL,  NSCLCadeno, OC,  OSCAR, PACA,  PRCA, SCLC,  UEC 238 YTCSRAVSLF GBC, HCC,  SCLC NSCLCother, OC,  RCC 239 IYTFSNVTF NHL 240 RVHANPLLI HCC 241 QKYYITGEAEGF OC BRCA, UEC 242 SYTPLLSYI SCLC GBM 243 ALFPMGPLTF NHL CLL 244 TYIDTRTVFL GC UEC 245 VLPLHFLPF HCC, HNSCC,  GBC, MEL, NHL NSCLCsquam,  UBC 246 KIYTTVLFANI GBC HCC 247 VHSYLGSPF AML 248 CWGPHCFEM GBM RCC 249 HQYGGAYNRV UEC 250 VYSDRQIYLL BRCA 251 DYLLSWLLF NHL CLL 252 RYLIIKYPF AML CCC 253 QYYCLLLIF CCC AML 254 KQHAWLPLTI CLL, NHL 255 VYLDEKQHAW CLL, NHL 256 QHAWLPLTI CLL, NHL 257 MLILFFSTI GBC, HCC,  BRCA HNSCC, MEL,  NSCLCadeno,  NSCLCother,  NSCLCsquam,  OC, OSCAR,  SCLC, UBC, UEC 258 VCWNPFNNTF NSCLCother, OC,  UEC RCC, SCLC 259 FFLFIPFF NSCLCadeno,  OC PRCA 260 FLFIPFFIIF NSCLCadeno,  OC PRCA 261 IMFCLKNFWW MEL 262 YIMFCLKNF MEL 263 AYVTEFVSL SCLC 264 AYAIPSASLSW MEL 265 LYQQSDTWSL CLL 266 TQIITFESF NSCLCadeno,  HNSCC NSCLCsquam,  OSCAR, UBC 267 QHMLPFWTDL BRCA, CCC,  GBC NSCLCadeno,  NSCLCsquam,  OC, OSCAR,  UBC, UEC 268 YQFGWSPNF HCC 269 FSFSTSMNEF UEC 270 GTGKLFWVF NHL CLL 271 INGDLVFSF UEC 272 IYFNHRCF CLL 273 VTMYLPLLL MEL 274 EYSLPVLTF GBM 275 PEYSLPVLTF GBM 276 KFLGSKCSF HNSCC,  UBC NSCLCsquam,  OSCAR 277 MSAIWISAF MEL 278 TYESVVTGFF HNSCC,  UBC NSCLCsquam,  OSCAR 279 KYKNPYGF BRCA, CRC, GC,  NSCLCsquam HNSCC, NHL,  NSCLCother, OC,  OSCAR, SCLC,  UEC 280 TIYSLEMKMSF NSCLCadeno PRCA 281 MDQNQVVWTF NSCLCother,  NSCLCadeno NSCLCsquam 282 ASYQQSTSSFF CLL 283 SYIVDGKII HNSCC, MEL,  CCC NSCLCsquam,  PACA 284 QFYSTLPNTI NSCLCother,  NSCLCadeno NSCLCsquam 285 YFLPGPHYF CLL, CRC, GBM,  NHL GC, HNSCC, MEL,  NSCLCadeno,  NSCLCsquam,  OC, OSCAR,  PACA, PRCA,  SCLC 286 HHTQLIFVF MEL,  HNSCC NSCLCsquam,  OSCAR 287 LVQPQAVLF NHL CLL 288 MGKGSISFLF GBM, PACA SCLC 289 RTLNEIYHW NHL 290 VTPKMLISF HCC 291 YTRLVLQF GBC, GC, UEC PACA 292 KMFPKDFRF PACA RCC 293 MYAYAGWFY HNSCC,  NSCLCsquam NSCLCadeno,  OSCAR 294 KMGRIVDYF GBC, GC, UEC PACA 295 KYNRQSMTL HCC 296 YQRPDLLLF NHL CLL 297 LKSPRLFTF UBC 298 TYETVMTFF UBC 299 FLPALYSLL CLL 300 LFALPDFIF CLL 301 RTALSSTDTF CLL 302 YQGSLEVLF UEC UBC 303 RFLDRGWGF BRCA, CRC, GBC,  CCC GC, HNSCC,  NSCLCadeno,  NSCLCother,  NSCLCsquam,  OSCAR, PACA,  UBC 304 YFGNPQKF CCC, GC,  OSCAR HNSCC,  NSCLCother,  NSCLCsquam,  PACA, UBC 305 RNAFSIYIL HNSCC MEL 306 RYILEPFFI HNSCC,  NSCLCsquam NSCLCadeno,  OSCAR 307 RILTEFELL GBC, GC CRC 308 AAFISVPLLI GBC, GC, PACA,  CRC UBC 309 AFISVPLLI GBC, GC, PACA,  CRC UBC 310 EFINGWYVL NHL CLL 311 IQNAILHLF GBC, HCC,  NHL HNSCC, MEL,  NSCLCadeno,  NSCLCother,  PACA, SCLC 312 YLCMLYALF GBM OC 313 IFMENAFEL HCC 314 SQHFNLATF AML 315 VYDYIPLLL UEC UBC 316 IWAERIMF BRCA PRCA 317 DWIWRILFLV BRCA, MEL,  GBC NSCLCsquam 318 VQADAKLLF GO, HNSCC,  CRC NSCLCsquam,  OSCAR, UBC 319 ATATLHLIF GBM 320 EVYQKIILKF GBC, MEL, OC,  SCLC 321 VYTVGHNLI HCC 322 SFISPRYSWLF AML 323 NYSPVTGKF MEL 324 RYFVSNIYL AML, GBC, MEL,  OC 325 IFMGAVPTL HNSCC, OC,  OSCAR, PRCA 326 VHMKDFFYF CLL, NHL 327 KWKPSPLLF CCC 328 IYLVGGYSW CLL, OC 329 YLGKNWSF AML 330 DYIQMIPEL SCLC 331 EYIDEFQSL SCLC 332 VYCSLDKSQF SCLC 333 RYADLLIYTY HNSCC, OC,  UBC, UEC 334 KVFGSFLTL NSCLCother, UEC 335 RYQSVIYPF NSCLCother, UEC 336 VYSDLHAFY SCLC 337 SHSDHEFLF BRCA, GBC, MEL,  NSCLCadeno,  NSCLCother, OC,  PRCA, UBC, UEC 338 VYLTWLPGL CLL, NHL 339 KQVIGIHTF CLL 340 FPPTPPLF AML, CLL, NHL 341 RYENVSILF GBM 342 MYGIVIRTI CRC, GBC, GC,  PACA 343 EYQQYHPSL CLL, NHL 344 YAYATVLTF PRCA 345 RYLEEHTEF UBC 346 TYIDFVPYI MEL, OC, RCC,  SCLC 347 AWLIVLLFL GBC, NHL, OC 348 RSWENIPVTF BRCA, MEL, NHL,  SCLC 349 IYMTTGVLL MEL 350 VYKWTEEKF CRC, PACA,  SCLC 351 GYFGTASLF NSCLCother 352 NAFEAPLTF AML, CLL, CRC,  HNSCC, NHL,  NSCLCsquam,  SCLC 353 AAFPGAFSF GBM 354 QYIPTFHVY GBM, HCC,  HNSCC,  NSCLCadeno, OC,  OSCAR, SCLC,  UBC 355 VYNNNSSRF MEL 356 YSLEHLTQF HCC 357 RALLPSPLF HCC 358 IYANVTEMLL HNSCC, OSCAR,  UBC 359 TQLPAPLRI GBM 360 LYITKVTTI UBC 361 KQPANFIVL GBC, GC, PACA 362 NYMDTDNLMF GBC, GC, PACA 363 QYGFNYNKF BRCA, HNSCC,  MEL, OSCAR 364 KQSQVVFVL MEL 365 KDLMKAYLF PRCA, SCLC 366 RLGEFVLLF HNSCC,  NSCLCsquam 367 HWSHITHLF CCC, GBC, GBM,  MEL 368 AYFVAMHLF GBM, OC, SCLC 369 NFYLFPTTF HNSCC, MEL,  OSCAR 370 TQMDVKLVF CLL 371 FRSWAVQTF CRC 372 LYHNWRHAF PRCA 373 IWDALERTF BRCA 374 MIFAVVVLF NHL 375 YYAADQWVF NHL 376 KYVGEVFNI PRCA 377 SLWREVVTF SCLC 378 VYAVISNIL GBM 379 KLPTEWNVL CLL 380 FYIRRLPMF MEL 381 IYTDITYSF MEL 382 SYPKELMKF UBC 383 PYFSPSASF CRC, GBC,  UBC HNSCC,  NSCLCadeno,  NSCLCsquam,  OC, OSCAR,  SCLC 384 RTRGWVQTL HOC,  CRC, GBC, GC,  NSCLCadeno,  RCC NSCLCsquam,  PACA, SCLC 385 GYFGNPQKF CCC, GC,  OSCAR HNSCC,  NSCLCother,  NSCLCsquam,  PACA, UBC 386 YQSRDYYNF BRCA, HCC,  PRCA 387 THAGVRLYF NSCLCother,  NSCLCsquam,  SCLC

TABLE-US-00012 TABLE 9b Expression scores. The table lists for each peptide the tumor types for which the exon is very highly over-expressed in tumors compared to a panel of normal tissues (+++), highly over-expressed in tumors compared to a panel of normal tissues (++) or over- expressed in tumors compared to a panel of normal tissues (+). The baseline for this score was calculated from measurements of the following relevant normal tissues: blood cells, blood vessels, brain, heart, liver, lung, adipose tissue, adrenal gland, bile duct, bone marrow, esophagus, eye, gallbladder, head-and-neck, kidney, large intestine, lymph node, pancreas, parathyroid gland, peripheral nerve, peritoneum, pituitary, pleura, skeletal muscle, skin, small intestine, spleen, stomach, thyroid gland, trachea, ureter, urinary bladder. In case expression data for several samples of the same tissue type were available, the arithmetic mean of all respective samples was used for the calculation. AML: acute myeloid leukemia; GBC: gallbladder cancer; HNSCC: head and neck squamous cell carcinoma; MEL: melanoma; NHL: non-Hodgkin lymphoma; NSCLCsquam: squamous cell non-small cell lung cancer; OC: ovarian cancer; OSCAR: esophageal cancer. Exon Expression in tumor types vs normal tissue panel highly very highly Seq over- over- over- ID Se- expressed expressed expressed No quence (+) (++) (+++) 463 VGGNV AML, HNSCC, GBC, TSNF MEL, NHL, NSCLCsquam, OSCAR OC 464 VGGNV HNSCC, NHL GBC, TSSF NSCLCsquam, OC

Example 3

[0343] In Vitro Immunogenicity for MHC Class I Presented Peptides

[0344] In order to obtain information regarding the immunogenicity of the TUMAPs of the present invention, the inventors performed investigations using an in vitro T-cell priming assay based on repeated stimulations of CD8+ T cells with artificial antigen presenting cells (aAPCs) loaded with peptide/MHC complexes and anti-CD28 antibody. This way the inventors could show immunogenicity for HLA-A*24:02 restricted TUMAPs of the invention, demonstrating that these peptides are T-cell epitopes against which CD8+ precursor T cells exist in humans (Table 10).

[0345] In Vitro Priming of CD8+ T Cells

[0346] In order to perform in vitro stimulations by artificial antigen presenting cells loaded with peptide-MHC complex (pMHC) and anti-CD28 antibody, the inventors first isolated CD8+ T cells from fresh HLA-A*24 leukapheresis products via positive selection using CD8 microbeads (Miltenyi Biotec, Bergisch-Gladbach, Germany) of healthy donors obtained from the University clinics Mannheim, Germany, after informed consent.

[0347] PBMCs and isolated CD8+ lymphocytes were incubated in T-cell medium (TCM) until use consisting of RPMI-Glutamax (Invitrogen, Karlsruhe, Germany) supplemented with 10% heat inactivated human AB serum (PAN-Biotech, Aidenbach, Germany), 100 U/ml Penicillin/100 μg/ml Streptomycin (Cambrex, Cologne, Germany), 1 mM sodium pyruvate (CC Pro, Oberdorla, Germany), 20 μg/ml Gentamycin (Cambrex). 2.5 ng/ml IL-7 (PromoCell, Heidelberg, Germany) and 10 U/ml IL-2 (Novartis Pharma, Nurnberg, Germany) were also added to the TCM at this step.

[0348] Generation of pMHC/anti-CD28 coated beads, T-cell stimulations and readout was performed in a highly defined in vitro system using four different pMHC molecules per stimulation condition and 8 different pMHC molecules per readout condition.

[0349] The purified co-stimulatory mouse IgG2a anti human CD28 Ab 9.3 (Jung et al., 1987) was chemically biotinylated using Sulfo-N-hydroxysuccinimidobiotin as recommended by the manufacturer (Perbio, Bonn, Germany). Beads used were 5.6 μm diameter streptavidin coated polystyrene particles (Bangs Laboratories, Illinois, USA).

[0350] pMHC used for positive and negative control stimulations were A*0201/MLA-001 (peptide ELAGIGILTV (SEQ ID NO. 461) from modified Melan-A/MART-1) and A*0201/DDX5-001 (YLLPAIVHI from DDX5, SEQ ID NO. 462), respectively.

[0351] 800.000 beads/200 μl were coated in 96-well plates in the presence of 4×12.5 ng different biotin-pMHC, washed and 600 ng biotin anti-CD28 were added subsequently in a volume of 200 μl. Stimulations were initiated in 96-well plates by co-incubating 1×10.sup.6 CD8+ T cells with 2×10.sup.5 washed coated beads in 200 μl TCM supplemented with 5 ng/ml IL-12 (PromoCell) for 3 days at 37° C. Half of the medium was then exchanged by fresh TCM supplemented with 80 U/ml IL-2 and incubating was continued for 4 days at 37° C. This stimulation cycle was performed for a total of three times. For the pMHC multimer readout using 8 different pMHC molecules per condition, a two-dimensional combinatorial coding approach was used as previously described (Andersen et al., 2012) with minor modifications encompassing coupling to 5 different fluorochromes. Finally, multimeric analyses were performed by staining the cells with Live/dead near IR dye (Invitrogen, Karlsruhe, Germany), CD8-FITC antibody clone SK1 (BD, Heidelberg, Germany) and fluorescent pMHC multimers. For analysis, a BD LSRII SORP cytometer equipped with appropriate lasers and filters was used. Peptide specific cells were calculated as percentage of total CD8+ cells. Evaluation of multimeric analysis was done using the FlowJo software (Tree Star, Oreg., USA). In vitro priming of specific multimer+ CD8+ lymphocytes was detected by comparing to negative control stimulations. Immunogenicity for a given antigen was detected if at least one evaluable in vitro stimulated well of one healthy donor was found to contain a specific CD8+ T-cell line after in vitro stimulation (i.e. this well contained at least 1% of specific multimer+ among CD8+ T-cells and the percentage of specific multimer+ cells was at least 1 Ox the median of the negative control stimulations).

[0352] In Vitro Immunogenicity for Acute Myeloid Leukemia, Breast Cancer, Cholangiocellular Carcinoma, Chronic Lymphocytic Leukemia, Colorectal Cancer, Gallbladder Cancer, Glioblastoma, Gastric Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma, Lung Cancer (Including Non-Small Cell Lung Cancer Adenocarcinoma, Squamous Cell Non-Small Cell Lung Cancer, and Small Cell Lung Cancer), Ovarian Cancer, Esophageal Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Urinary Bladder Carcinoma, Uterine and Endometrial Cancer Peptides

[0353] For tested HLA class I peptides, in vitro immunogenicity could be demonstrated by generation of peptide specific T-cell lines. Exemplary flow cytometry results after TUMAP-specific multimer staining for 2 peptides of the invention are shown in FIGS. 3A-3G together with corresponding negative controls. Results for 47 peptides from the invention are summarized in Table 10a and Table 10b.

TABLE-US-00013 TABLE 10a in vitro immunogenicity of HLA class I peptides of the invention Exemplary results of in vitro immunogenicity experiments conducted by the applicant for the peptides of the invention. <20% = +; 20%-49% = ++; 50%-69% = +++; >=70% = ++++ Seq Wells ID Peptide positive No Sequence Code [%] 390 KYKDYFPVI MAGEC2-003 + 392 SYEKVINYL MAGEA9-001 + 393 SYNDALLTF TRPM8-004 +++ 395 NYEDHFPLL MAGEA10- ++ 002 398 GYLQGLVSF KLK4-001 ++ 399 VWSNVTPLKF MMP12-014 + 400 RYLEKFYGL MMP12-006 + 402 TYKYVDINTF MMP12-004 + 406 KYLEKYYNL MMP1-001 ++ 408 VWSDVTPLTF MMP11-001 + 409 VYTFLSSTL ESR1-006 + 411 VYPPYLNYL PGR-002 ++++ 415 KYEKIFEML CT45-002 + 416 VFMKDGFFYF MMP1-002 + 420 VYEKNGYIYF MMP13-001 ++++ 422 VWSDVTPLNF MMP13-002 + 429 YYSKSVGFMQW FAM111B- ++ 008 433 NYTSLLVTW PTP-018 + 434 VYDTMIEKF PTP-016 + 436 KYLQVVGMF OXTR-001 + 440 NYGVLHVTF NLRP11-002 + 447 EYIRALQQL ASCL1-001 + 448 PFLPPAACFF ASCL1-002 + 450 QYDPTPLTW ADAMTS12- + 002 453 YYTVRNFTL PTP-014 + 455 KYLSIPTVF UGT1A3-001 +

TABLE-US-00014 TABLE 10b in vitro immunogenicity of HLA class I peptides of the invention Exemplary results of in vitro immunogenicity experiments conducted by the applicant for the peptides of the invention. <20% = +; 20%-49% = ++; 50%-69% = +++; >=70% = ++++ Seq Wells ID Peptide positive No Sequence Code [%] 1 IFPKTGLLII MAGEA4-008 ++ 5 LQPQPQLFFSF POT-002 ++ 22 VYSSFVFNL NLRP4-006 + 23 VYSSFVFNLF NLRP4-007 ++ 26 TYFFVDNQYW MMP12-020 + 32 FYPEVELNF MMP1-009 +++ 38 RYAHTLVTSVLF ITIH6-003 ++ 44 FYHEDMPLW FCRL5-004 + 47 SYLWTDNLQEF DNAH17-003 + 52 SWHKATFLF COL24-002 + 56 FYKLIQNGF FLT3-010 + 58 IYYSHENLI F5-005 ++ 63 LYIDKGQYL HMCN1-011 + 76 IYIYPFAHW NPFFR2-002 +++ 77 LYGFFFKI BTBD16-002 ++++ 78 TYSKTIALYGF BTBD16-004 ++ 79 FYIVTRPLAF SUCN-002 + 81 AYLKLLPMF SLC5A4-001 + 86 SYLPTAERL SYT12-001 + 87 NYTRLVLQF GABRP-004 + 88 TYVPSTFLV GABRP-005 +

Example 4

[0354] Synthesis of Peptides

[0355] All peptides were synthesized using standard and well-established solid phase peptide synthesis using the Fmoc-strategy. Identity and purity of each individual peptide have been determined by mass spectrometry and analytical RP-HPLC. The peptides were obtained as white to off-white lyophilizes (trifluoro acetate salt) in purities of >50%. All TUMAPs are preferably administered as trifluoro-acetate salts or acetate salts, other salt-forms are also possible.

Example 5

[0356] MHC Binding Assays

[0357] Candidate peptides for T cell based therapies according to the present invention were further tested for their MHC binding capacity (affinity). The individual peptide-MHC complexes were produced by UV-ligand exchange, where a UV-sensitive peptide is cleaved upon UV-irradiation, and exchanged with the peptide of interest as analyzed. Only peptide candidates that can effectively bind and stabilize the peptide-receptive MHC molecules prevent dissociation of the MHC complexes. To determine the yield of the exchange reaction, an ELISA was performed based on the detection of the light chain (β2m) of stabilized MHC complexes. The assay was performed as generally described in Rodenko et al. (Rodenko et al., 2006)

[0358] 96 well MAXISorp plates (NUNC) were coated over night with 2 ug/ml streptavidin in PBS at room temperature, washed 4× and blocked for 1 h at 37° C. in 2% BSA containing blocking buffer. Refolded HLA-A*02:01/MLA-001 monomers served as standards, covering the range of 15-500 ng/ml. Peptide-MHC monomers of the UV-exchange reaction were diluted 100-fold in blocking buffer. Samples were incubated for 1 h at 37° C., washed four times, incubated with 2 ug/ml HRP conjugated anti-β2m for 1 h at 37° C., washed again and detected with TMB solution that is stopped with NH.sub.2SO.sub.4. Absorption was measured at 450 nm. Candidate peptides that show a high exchange yield (preferably higher than 50%, most preferred higher than 75%) are generally preferred for a generation and production of antibodies or fragments thereof, and/or T cell receptors or fragments thereof, as they show sufficient avidity to the MHC molecules and prevent dissociation of the MHC complexes.

TABLE-US-00015 TABLE 11 MHC class I binding scores. Binding of HLA- class I restricted peptides to HLA-A*24  was ranged by peptide exchange yield: >10% = +; >20% = ++; >50 = +++; >75% = ++++ Seq ID Peptide Peptide No Sequence Code exchange 1 IFPKTGLLII MAGEA4-008 ++++ 2 LYAPTILLW AFP-001 ++++ 3 KFLTHDVLTELF TRPM8-009 ++++ 5 LQPQPQLFFSF POT-002 ++++ 6 IVTFMNKTLGTF ADAM29-001 + 9 TYINSLAIL TGM4-003 ++++ 10 QYPEFSIEL TGM4-001 +++ 11 RAMCAMMSF TGM4-002 ++ 12 KYMSRVLFVY CHRNA9-002 ++ 13 KYYIATMAL CHRNA9-003 +++ 14 YYIATMALI CHRNA9-004 ++++ 15 FMVIAGMPLF SLC6A3-001 ++ 16 GYFLAQYLM TRPM8-008 +++ 17 IYPEAIATL SLC6A3-002 ++++ 18 KYVDINTFRL MMP12-018 ++++ 20 ELMAHPFLL CYP4Z-002 ++ 21 LYMRFVNTHF SPINK2-002 ++ 22 VYSSFVFNL NLRP4-006 +++ 23 VYSSFVFNLF NLRP4-007 +++ 24 KMLPEASLLI NLRP4-004 ++ 25 MLPEASLLI NLRP4-005 ++++ 26 TYFFVDNQYW MMP12-020 ++++ 27 LSCTATPLF KHDC1L-001 +++ 28 FWFDSREISF OR51 E2-002 ++++ 29 IYLLLPPVI OR51 E2-004 ++++ 30 RQAYSVYAF SLC45A3-005 ++ 31 KQMQEFFGL MMP1-010 +++ 32 FYPEVELNF MMP1-009 ++++ 33 FYQPDLKYLSF NLRP4-003 ++++ 34 LIFALALAAF GAST-001 + 35 FSSTLVSLF MAGEC1-003 ++ 36 VYLASVAAF SLC45A3-006 ++++ 37 ISFSDTVNVW ITIH6-001 + 38 RYAHTLVTSVLF ITIH6-003 ++++ 39 KTYLPTFETTI ENP-002 ++ 40 NYPEGAAYEF ESR1-008 ++++ 41 IYFATQVVF SLC45A3-004 ++++ 42 VYDSIWCNM SCGB2A1-001 ++++ 43 KYKDHFTEI MAGEB1-001 ++++ 44 FYHEDMPLW FCRL5-004 ++++ 45 YGQSKPWTF PAX3-001 ++ 46 IYPDSIQEL LOC-019 +++ 47 SYLWTDNLQEF DNAH17-003 ++++ 48 AWSPPATLFLF LOXL4-003 ++++ 49 QYLSIAERAEF MSX-001 ++++ 50 RYFDENIQKF HEPHL-004 ++++ 51 YFDENIQKF HEPHL-006 +++ 52 SWHKATFLF COL24-002 ++++ 53 LFQRVSSVSF HMCN1-010 +++ 54 SYQEAIQQL NEFH-003 +++ 55 AVLRHLETF CDK6-006 ++ 56 FYKLIQNGF FLT3-010 ++++ 58 IYYSHENLI F5-005 ++++ 59 VFPLVTPLL PTP-042 ++++ 60 RYSPVKDAW KLHDC7B-006 ++++ 61 RIFTARLYF AICD-001 +++ 62 VYIVPVIVL OXTR-002 ++++ 63 LYIDKGQYL HMCN1-011 ++++ 64 QFSHVPLNNF ALX1-001 ++ 66 IYKDYYRYNF PLA2G2D-001 ++++ 67 SYVLQIVAI PTP-041 +++ 68 VYKEDLPQL EML-002 ++++ 69 KWFDSHIPRW ERV-002 ++++ 70 RYTGQWSEW IL9R-001 ++++ 71 RYLPNPSLNAF CYP1A1-002 ++++ 72 RWLDGSPVTL CLEC17-005 ++++ 73 YFCSTKGQLF FCRL2-004 ++++ 74 NYVLVPTMF CAPN6-003 ++++ 75 VYEHNHVSL BTBD16-006 +++ 76 IYIYPFAHW NPFFR2-002 ++++ 77 LYGFFFKI BTBD16-002 ++++ 78 TYSKTIALYGF BTBD16-004 ++++ 79 FYIVTRPLAF SUCN-002 +++ 80 SYATPVDLW CDK6-007 ++++ 81 AYLKLLPMF SLC5A4-001 ++++ 82 SYLENSASW DLX5-003 ++++ 83 VLQGEFFLF KBTBD8-005 ++++ 84 YTIERYFTL GABRP-007 ++++ 85 KYLSIPTVFF UGT1A3-002 ++++ 86 SYLPTAERL SYT12-001 ++++ 87 NYTRLVLQF GABRP-004 ++++ 88 TYVPSTFLV GABRP-005 ++++ 89 TYVPSTFLVVL GABRP-006 ++++ 90 TDLVQFLLF MAGEA10-003 ++ 92 RALTETIMF ALP-011 ++ 93 TDWSPPPVEF FAM178B-001 +++ 94 THSGGTNLF MMP12-019 ++ 95 IGLSVVHRF OR51 E2-003 ++++ 96 SHIGWLAF OR51 E2-005 ++ 98 LQIPVSPSF MAGEC1-004 + 99 ASAALTGFTF SLC45A3-003 ++ 100 KVWSDVTPLTF MMP11-023 +++ 101 VYAVSSDRF DCX-001 ++++ 102 VLASAHILQF BTBD16-005 ++ 103 EMFFSPQVF ACTL8-002 ++ 104 GYGLTRVQPF ACTL8-003 ++ 106 LYAFLGSHF KISS1R-003 ++++ 108 WFFQGAQYW MMP11-024 ++ 109 AQHSLTQLF GPC2-002 ++ 110 VYSNPDLFW TRDV3-002 ++++ 111 IRPDYSFQF TRDV3-001 ++ 112 LYPDSVFGRLF SMC1B-003 ++++ 113 ALMSAFYTF MMP11-020 ++++ 114 KALMSAFYTF MMP11-022 +++ 115 IMQGFIRAF PAE-002 ++ 116 TYFFVANKY MMP1-011 + 117 RSMEHPGKLLF ESR1-010 +++ 118 IFLPFFIVF ADAM18-001 ++++ 119 VWSCEGCKAF ESR-001 ++ 120 VYAFMNENF QRFPR-004 ++++ 121 RRYFGEKVAL ANO7-005 ++ 123 FFLQESPVF ABCC11-004 ++++ 124 EYNVFPRTL MMP13-004 ++ 125 LYYGSILYI OR9-001 ++++ 126 YSLLDPAQF SOX14-002 +++ 127 FLPRAYYRW ANO7-001 ++ 128 AFQNVISSF NMUR2-003 ++++ 129 IYVSLAHVL ANO7-002 ++++ 130 RPEKVFVF COL11A1-005 ++ 131 MHRTWRETF ANO7-004 ++ 133 FFYVTETTF TERT-003 ++++ 134 IYSSQLPSF TFEC-004 ++++ 135 KYKQHFPEI MAGEB17-001 +++ 136 YLKSVQLF RFX8-001 ++ 137 ALFAVCWAPF QRFPR-002 ++ 138 MMVTVVALF QRFPR-003 +++ 139 AYAPRGSIYKF HHIPL2-001 ++++ 140 IFQHFCEEI SMC1B-002 ++ 141 QYAAAITNGL SALL3-002 +++ 142 PYWWNANMVF NOTU-001 ++++ 143 KTKRWLWDF COL11A1-004 +++ 144 LFDHGGTVFF ANO7-003 +++ 145 MYTIVTPML OR1N1-001 ++++ 146 NYFLDPVTI TRI-005 +++ 148 MLPQIPFLLL COL10-001 ++ 149 TQFFIPYTI COL10-002 ++ 150 FIPVAWLIF MRGPRX4-001 +++ 151 RRLWAYVTI ITIH6-002 + 152 MHPGVLAAFLF MMP13-005 +++ 153 AWSPPATLF LOXL4-002 ++++ 154 DYSKQALSL LAMC2-018 ++ 155 PYSIYPHGVTF F5-006 ++++ 156 IYPHGVTFSP F5-004 + 157 SIYPHGVTF F5-007 ++ 158 SYLKDPMIV DDX53-001 +++ 159 VFQPNPLF WISP3-002 ++ 160 YIANLISCF GLYATL3-001 ++ 161 ILQAPLSVF FCRL5-005 ++ 162 YYIGIVEEY HEPHL-007 +++ 163 YYIGIVEEYW HEPHL-008 ++++ 164 MFQEMLQRL TRIML2-001 + 165 KDQPQVPCVF NAT1-001 + 166 MMALWSLLHL ZAC-001 + 167 LQPPWTTVF FCRL5-006 ++ 168 LSSPVHLDF FCRL5-007 ++++ 169 MYDLHHLYL EPY-001 ++++ 170 IFIPATILL ACSM1-001 ++++ 171 LYTVPFNLI SLC45A2-006 ++++ 172 RYFIAAEKILW HEPHL-005 ++++ 173 RYLSVCERL NKX-001 ++++ 174 TYGEEMPEEI DNAH17-004 ++ 175 SYFEYRRLL LAMC2-019 ++ 176 TQAGEYLLF FLT3-012 ++++ 177 KYLITTFSL NLRP2-008 ++++ 178 AYPQIRCTW FLT3-009 ++++ 179 MYNMVPFF DCT-002 +++ 180 IYNKTKMAF SLCO6-001 ++++ 181 IHGIKFHYF NMUR2-004 +++ 182 AQGSGTVTF FCRL3-004 ++ 183 YQVAKGMEF FLT3-014 + 184 VYVRPRVF HMCN1-013 ++ 185 LYICKVELM CTL-001 ++++ 186 RRVTWNVLF BTBD17-003 ++ 187 KWFNVRMGFGF LIN-001 ++ 188 SLPGSFIYVF HMCN1-012 ++ 189 FYPDEDDFYF MYCN-002 +++ 190 IYIIMQSCW FLT3-011 +++ 191 MSYSCGLPSL KRT33A-001 +++ 192 CYSFIHLSF NLR-006 ++++ 193 KYKPVALQCIA HMCN1-009 ++ 195 IYNEHGIQQI COL11A1-003 ++++ 196 VGRSPVFLF COL11A1-006 ++ 198 VLAPVSGQF FCRL5-009 +++ 199 MFQFEHIKW FBXW10-001 ++ 200 LYMSVEDFI STK31-001 ++++ 201 VFPSVDVSF PTP-043 ++++ 202 VYDTMIEKFA PTP-044 ++ 203 VYPSESTVM PTP-045 ++ 204 WQNVTPLTF MMP16-002 ++ 205 ISWEVVHTVF HMCN1-008 ++++ 206 EVVHTVFLF HMCN1-007 ++ 207 IYKFIMDRF FOXB1-001 ++++ 208 QYLQQQAKL FOXB1-002 ++++ 209 DIYVTGGHLF KLHDC7B-005 +++ 210 EAYSYPPATI HMCN1-006 +++ 211 MLYFAPDLIL PGR-004 ++ 212 VYFVQYKIM IL22RA2-001 + 213 FYNRLTKLF OFCC-001 ++++ 214 YIPMSVMLF HTR7-002 +++ 215 KASKITFHW PTP-038 ++ 216 RHYHSIEVF LOXL4-004 ++ 217 QRYGFSSVGF RHBG-001 ++++ 218 FYFYNCSSL ERV-001 ++++ 219 KVVSGFYYI CCR8-003 + 220 TYATHVTEI CCR8-004 ++++ 222 HYHAESFLF HEPHL-003 ++++ 223 KLRALSILF PTP-039 + 224 AYLQFLSVL GREB-002 ++++ 225 ISMSATEFLL CYP1A1-001 +++ 226 TYSTNRTMI FLT3-013 ++++ 227 YLPNPSLNAF CYP1A1-003 ++ 228 VYLRIGGF WNT7A-002 ++ 229 CAMPVAMEF KBTBD8-003 ++ 230 RWLSKPSLL KBTBD8-004 ++++ 231 KYSVAFYSLD LAMA1-008 ++ 232 IWPGFTTSI PIWIL1-003 ++++ 234 RYKMLIPF NLRP2-010 +++ 235 VYISDVSVY CLECL-003 ++++ 236 LHLYCLNTF PGR-003 +++ 238 YTCSRAVSLF OTOG-001 ++ 239 IYTFSNVTF BTN1-003 ++++ 240 RVHANPLLI APOB-081 + 241 QKYYITGEAEGF ESR1-009 ++++ 242 SYTPLLSYI C1orf94-002 ++++ 243 ALFPMGPLTF LILRA4-003 ++ 244 TYIDTRTVFL CAPN6-005 ++++ 245 VLPLHFLPF HBG2-001 ++++ 246 KIYTTVLFANI NPFFR2-003 ++++ 247 VHSYLGSPF MPL-001 ++ 249 HQYGGAYNRV DLX5-002 ++ 250 VYSDRQIYLL ABCC11-006 ++++ 251 DYLLSWLLF CNR2-003 ++++ 252 RYLIIKYPF SUCN-003 +++ 254 KQHAWLPLTI TCL1A-003 + 255 VYLDEKQHAW TCL1A-005 ++++ 256 QHAWLPLTI TCL1A-004 + 258 VCWNPFNNTF RNF183-001 +++ 259 FFLFIPFF ADAM2-001 ++ 263 AYVTEFVSL SCN3A-001 ++++ 264 AYAIPSASLSW HMCN1-005 ++ 265 LYQQSDTWSL KIAA140-001 ++ 266 TQIITFESF CSF2-001 ++ 267 QHMLPFWTDL NLRP2-009 +++ 269 FSFSTSMNEF CAPN6-001 ++ 270 GTGKLFWVF BTL-003 + 271 INGDLVFSF CAPN6-002 ++ 272 IYFNHRCF SFMBT1-001 +++ 273 VTMYLPLLL GPR143-001 ++ 274 EYSLPVLTF PTP-037 +++ 275 PEYSLPVLTF PTP-040 ++++ 276 KFLGSKCSF HAS3-003 ++++ 278 TYESVVTGFF HAS3-004 ++ 279 KYKNPYGF MMP20-001 + 280 TIYSLEMKMSF GLB1L3-001 ++ 281 MDQNQVVWTF ROS-008 +++ 282 ASYQQSTSSFF FAM82A1-001 ++ 283 SYIVDGKII PSG9-001 + 284 QFYSTLPNTI ROS-009 + 285 YFLPGPHYF SOX30-001 ++++ 288 MGKGSISFLF PCSK1-001 ++ 289 RTLNEIYHW FOXP3-001 ++ 290 VTPKMLISF OR5H8P-001 + 291 YTRLVLQF GABRP-008 ++ 292 KMFPKDFRF TTLL6-001 ++ 294 KMGRIVDYF GABRP-003 ++++ 295 KYNRQSMTL APOB-080 ++++ 296 YQRPDLLLF GEN-004 ++ 297 LKSPRLFTF BTBD16-001 ++ 298 TYETVMTFF BTBD16-003 ++++ 299 FLPALYSLL CXCR3-001 +++ 300 LFALPDFIF CXCR3-002 ++ 302 YQGSLEVLF MROH2A-006 ++ 303 RFLDRGWGF ADAMTS12-005 ++++ 306 RYILEPFFI SLC7A11-007 ++++ 307 RILTEFELL TRIM31-001 +++ 308 AAFISVPLLI TAS2R38-002 ++++ 309 AFISVPLLI TAS2R38-003 ++++ 310 EFINGWYVL MCOLN2-002 ++ 311 IQNAILHLF OR51B5-001 ++++ 312 YLCMLYALF KCNK18-001 ++ 313 IFMENAFEL APOB-079 ++++ 314 SQHFNLATF DNMT3B-003 ++ 315 VYDYIPLLL MROH2A-005 ++++ 316 IWAERIMF TDRD1-001 +++ 318 VQADAKLLF C20-002 + 319 ATATLHLIF PCD-007 + 320 EVYQKIILKF PASD-001 ++++ 321 VYTVGHNLI KLB-003 ++++ 322 SFISPRYSWLF SPNS3-005 ++++ 323 NYSPVTGKF OTOL-001 ++++ 325 IFMGAVPTL LPAR3-001 ++++ 326 VHMKDFFYF DYRK4-001 ++++ 327 KWKPSPLLF GPR126-002 ++++ 328 IYLVGGYSW KLHL14-007 ++++ 329 YLGKNWSF SPNS3-006 ++ 330 DYIQMIPEL RTL-002 ++++ 331 EYIDEFQSL RTL-003 ++++ 332 VYCSLDKSQF RTL-004 ++++ 333 RYADLLIYTY MYO3B-005 ++++ 334 KVFGSFLTL AGTR2-001 ++ 335 RYQSVIYPF AGTR2-002 ++++ 336 VYSDLHAFY MANEAL-004 ++++ 337 SHSDHEFLF ARSH-001 + 338 VYLTWLPGL IFNLR-001 ++++ 339 KQVIGIHTF SFMBT1-002 + 340 FPPTPPLF BCL11A-002 + 341 RYENVSILF ADCY8-001 ++++ 342 MYGIVIRTI NPSR-001 ++++ 343 EYQQYHPSL CLEC4C-001 ++++ 344 YAYATVLTF ABCC4-002 ++ 345 RYLEEHTEF MROH2A-003 ++++ 346 TYIDFVPYI TEX15-001 ++++ 348 RSWENIPVTF C18orf54-001 ++ 349 IYMTTGVLL TDRD9-002 ++++ 350 VYKWTEEKF TSPE-001 ++++ 351 GYFGTASLF SLC16A14-001 ++++ 352 NAFEAPLTF BRCA2-004 +++ 353 AAFPGAFSF CRB2-002 ++ 354 QYIPTFHVY SLC44A5-003 ++++ 355 VYNNNSSRF MY010-003 ++++ 356 YSLEHLTQF ZCCHC16-001 ++ 357 RALLPSPLF SPATA31D1-001 ++ 358 IYANVTEMLL CYP27C-001 ++++ 359 TQLPAPLRI GPR45-001 ++ 360 LYITKVTTI FSTL4-002 ++++ 361 KQPANFIVL LOC1001246-001 ++ 362 NYMDTDNLMF LOC1001246-002 ++++ 363 QYGFNYNKF PNLD-002 ++++ 365 KDLMKAYLF TXNDC16-006 +++ 366 RLGEFVLLF TGM6-001 +++ 367 HWSHITHLF DPY19L1-003 ++++ 368 AYFVAMHLF TENM4-007 ++++ 369 NFYLFPTTF PNLD-001 ++++ 370 TQMDVKLVF GEN-003 ++ 371 FRSWAVQTF NOS2-002 ++ 372 LYHNWRHAF PDE11-002 ++++ 373 IWDALERTF ABCC11-005 ++ 375 YYAADQWVF CCR4-004 ++++ 376 KYVGEVFNI DMXL1-001 ++++ 377 SLWREVVTF CEP250-004 +++ 378 VYAVISNIL TNR-003 ++++ 379 KLPTEWNVL AKAP13-005 ++++ 380 FYIRRLPMF CHRNA6-001 ++++ 381 IYTDITYSF CHRNA6-002 ++++ 382 SYPKELMKF MROH2A-004 ++++ 383 PYFSPSASF SPER-001 ++++ 385 GYFGNPQKF LAMA3-002 ++++ 386 YQSRDYYNF AR-002 ++++ 387 THAGVRLYF NUP155-012 ++ 463 VGGNVTSNF CT45-004 +++ 464 VGGNVTSSF CT45-005 +++

REFERENCE LIST

[0359] Allison, J. P. et al., Science. 270 (1995): 932-933 [0360] Andersen, R. S. et al., Nat Protoc. 7 (2012): 891-902 [0361] Appay, V. et al., Eur J Immunol. 36 (2006): 1805-1814 [0362] Banchereau, J. et al., Cell. 106 (2001): 271-274 [0363] Beatty, G. et al., J Immunol. 166 (2001): 2276-2282 [0364] Beggs, J. D., Nature. 275 (1978): 104-109 [0365] Benjamini, Y. et al., Journal of the Royal Statistical Society Series B (Methodological). Vol. 57 (1995): 289-300 [0366] Boulter, J. M. et al., Protein Eng. 16 (2003): 707-711 [0367] Braumuller, H. et al., Nature. (2013) [0368] Brossart, P. et al., Blood. 90 (1997): 1594-1599 [0369] Bruckdorfer, T. et al., Curr Pharm Biotechnol. 5 (2004): 29-43 [0370] Card, K. F. et al., Cancer Immunol Immunother. 53 (2004): 345-357 [0371] Cohen, C. J. et al., J Mol Recognit. 16 (2003a): 324-332 [0372] Cohen, C. J. et al., J Immunol. 170 (2003b): 4349-4361 [0373] Cohen, S. N. et al., Proc Natl Acad Sci USA. 69 (1972): 2110-2114 [0374] Coligan, J. E. et al., Current Protocols in Protein Science. (1995) [0375] Colombetti, S. et al., J Immunol. 176 (2006): 2730-2738 [0376] Dengjel, J. et al., Clin Cancer Res. 12 (2006): 4163-4170 [0377] Denkberg, G. et al., J Immunol. 171 (2003): 2197-2207 [0378] Falk, K. et al., Nature. 351 (1991): 290-296 [0379] Follenzi, A. et al., Nat Genet. 25 (2000): 217-222 [0380] Fong, L. et al., Proc Natl Acad Sci USA. 98 (2001): 8809-8814 [0381] Gabrilovich, D. I. et al., Nat Med. 2 (1996): 1096-1103 [0382] Gattinoni, L. et al., Nat Rev Immunol. 6 (2006): 383-393 [0383] Gnjatic, S. et al., Proc Natl Acad Sci USA. 100 (2003): 8862-8867 [0384] Godkin, A. et al., Int Immunol. 9 (1997): 905-911 [0385] Gragert, L. et al., Hum Immunol. 74 (2013): 1313-1320 [0386] Green, M. R. et al., Molecular Cloning, A Laboratory Manual. 4th (2012) [0387] Greenfield, E. A., Antibodies: A Laboratory Manual. 2nd (2014) [0388] Gustafsson, C. et al., Trends Biotechnol. 22 (2004): 346-353 [0389] Hwang, M. L. et al., J Immunol. 179 (2007): 5829-5838 [0390] Jung, G. et al., Proc Natl Acad Sci USA. 84 (1987): 4611-4615 [0391] Kibbe, A. H., Handbook of Pharmaceutical Excipients. rd (2000) [0392] Krieg, A. M., Nat Rev Drug Discov. 5 (2006): 471-484 [0393] Kuball, J. et al., Blood. 109 (2007): 2331-2338 [0394] Liddy, N. et al., Nat Med. 18 (2012): 980-987 [0395] Ljunggren, H. G. et al., J Exp Med. 162 (1985): 1745-1759 [0396] Longenecker, B. M. et al., Ann N Y Acad Sci. 690 (1993): 276-291 [0397] Lukas, T. J. et al., Proc Natl Acad Sci USA. 78 (1981): 2791-2795 [0398] Lundblad, R. L., Chemical Reagents for Protein Modification. 3rd (2004) [0399] Meziere, C. et al., J Immunol. 159 (1997): 3230-3237 [0400] Morgan, R. A. et al., Science. 314 (2006): 126-129 [0401] Mortara, L. et al., Clin Cancer Res. 12 (2006): 3435-3443 [0402] Mueller, L. N. et al., J Proteome Res. 7 (2008): 51-61 [0403] Mueller, L. N. et al., Proteomics. 7 (2007): 3470-3480 [0404] Mumberg, D. et al., Proc Natl Acad Sci USA. 96 (1999): 8633-8638 [0405] Pinheiro, J. et al., nlme: Linear and Nonlinear Mixed Effects Models (CRANR-projectorg/package=nlme) (2015) [0406] Plebanski, M. et al., Eur J Immunol. 25 (1995): 1783-1787 [0407] Porta, C. et al., Virology. 202 (1994): 949-955 [0408] Rammensee, H. et al., Immunogenetics. 50 (1999): 213-219 [0409] Rini, B. I. et al., Cancer. 107 (2006): 67-74 [0410] Rock, K. L. et al., Science. 249 (1990): 918-921 [0411] Rodenko, B. et al., Nat Protoc. 1 (2006): 1120-1132 [0412] Saiki, R. K. et al., Science. 239 (1988): 487-491 [0413] Schmitt, T. M. et al., Hum Gene Ther. 20 (2009): 1240-1248 [0414] Scholten, K. B. et al., Clin Immunol. 119 (2006): 135-145 [0415] Seeger, F. H. et al., Immunogenetics. 49 (1999): 571-576 [0416] Sherman, F. et al., Laboratory Course Manual for Methods in Yeast Genetics. (1986) [0417] Singh-Jasuja, H. et al., Cancer Immunol Immunother. 53 (2004): 187-195 [0418] Small, E. J. et al., J Clin Oncol. 24 (2006): 3089-3094 [0419] Sturm, M. et al., BMC Bioinformatics. 9 (2008): 163 [0420] Teufel, R. et al., Cell Mol Life Sci. 62 (2005): 1755-1762 [0421] Tran, T. T. et al., Photochem Photobiol. 90 (2014): 1136-1143 [0422] Walter, S. et al., J Immunol. 171 (2003): 4974-4978 [0423] Walter, S. et al., Nat Med. 18 (2012): 1254-1261 [0424] Willcox, B. E. et al., Protein Sci. 8 (1999): 2418-2423 [0425] Zaremba, S. et al., Cancer Res. 57 (1997): 4570-4577 [0426] Zufferey, R. et al., J Virol. 73 (1999): 2886-2892